Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 424  |  Browse by Industry: Previous - Next | All     monitor keywords
Recent  |  14:  |  |  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
02/05/2015 > 195 patent applications in 107 patent subcategories.

20150037248 - Il-1beta neutralizing human monoclonal antibodies: The present invention is directed to antigen binding proteins and in particular to IL-1β antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.... Agent: Agency For Science, Technology And Research

20150037249 - Uses of porous nanostructure in delivery: The present invention relates to methods for delivering at least one agent unto or into a biological sample or a biological subject. The methods comprise a step of contacting the biological sample or subject with a payload-carrying nanostructure. The nanostructure can be a porous low density nanostructure.... Agent:

20150037250 - Contrast agent: According to one embodiment, a contrast agent includes a blood vessel contrast enhancement particles configured to enhance contrast of a blood vessel of an object and a diseased tissue contrast enhancement particles configured to enhance contrast of a diseased tissue of the object. The blood vessel contrast enhancement particles have... Agent: Toshiba Medical Systems Corporation

20150037251 - Mammalian homologues of flower, their use in cancer diagnostics, prevention and treatment: The invention relates inhibiting nucleic acids directed at mammalian homologues of the Drosophila fwe gene (Flower) and to antibodies against the respective proteins, and their use in diagnosing, preventing and treating cancer.... Agent: Centro Nacional De Investigaciones Oncologicas

20150037253 - Metal complexes as imaging agents: The present invention relates to copper, gallium and technetium coordinated thiosemicarbazone-pyridylhydrazine (substituted at the pyridine ring with a substituted benzothiazole or stilbene moiety) complexes and methods thereof. Such compounds possess utility in PET imaging and diagnosis of amyloid diseases.... Agent:

20150037252 - Method for the treatment of a solid tumour: The present invention relates generally to a method of treating a neoplastic condition and to agents useful for same. More particularly, the present invention is directed to a method of facilitating the treatment of a solid tumor in a localised manner via the co-administration of particulate material and a cellular... Agent: The University Of Sydney

20150037254 - Contrast agent for photoacoustic imaging: Provided is a particle having a large photoacoustic signal per unit dye, the particle including: one of a hydrophobic metal naphthalocyanine dye and a hydrophobic metal phthalocyanine dye; one of an oil, a fatty acid, and a fatty acid ester as a matrix material; and a surfactant, in which a... Agent:

20150037255 - Phthalocyanine dye-containing contrast agent for photoacoustic imaging: To provide a particle promoting hydrophobic metal phthalocyanine aggregation, having absorption in a wavelength region suitable for a photoacoustic imaging method and having a high molar absorbance coefficient per particle by increasing the weight percentage of the dye in the particle. The particle of the present invention is a particle... Agent:

20150037256 - Use of silver(i) complexes as anticancer agents: The present invention relates to the use of silver(l) monophosphine complexes as Active Pharmaceutical Ingredients (API's), including anticancer agents, for the treatment, diagnosis and/or prevention of cancer. The present invention also relates to pharmaceutical compositions containing such complexes and further extends to a method of treating or diagnosing a subject/patient... Agent:

20150037257 - Compositions and methods for high-throughput screening in skin fibroblasts with an alpha-synuclein triplication: Human-derived fibroblast cells with copy number variation for alpha-synuclein, and methods of use thereof, are provided. For example, compositions and methods for high through-put screening of potential therapies for neurodegenerative disease such as Parkinson's disease are provided.... Agent:

20150037261 - New class of diazepine derivative chelating agents and complexes with paramagnetic metals thereof as mri contrast agents: The present invention relates to a new class of diazepine-derivatives as chelating agents for paramagnetic metal ions, the process for their preparation, and use of such paramagnetic complexes as contrast agents, particularly suitable for Magnetic Resonance Imaging (MRI) analysis.... Agent: Bracco Imaging S.p.a.

20150037260 - Chemical reaction by combination of gas-phase and wet-chemical methods: The invention provides a new apparatus (20) and method for producing entirely new types of nanoparticles exhibiting novel properties. The apparatus comprises a vacuum chamber (22) containing a gas and feed means (1) for feeding a liquid jet (26) into the chamber and through the gas. The invention extends to... Agent:

20150037258 - Infection indicating medical devices: Provided herein is an implantable medical device capable of self-reporting microbial growth adjacent the site of the implanted device.... Agent:

20150037259 - Polyelectrolyte-coated polymer dots and related methods: Polymer nanoparticles and related methods include polymer dots having a coating including a polyelectrolyte polymer. The polymer dots can have a polyelectrolyte coating that can improve colloidal stability of the particles as compared to polymer dots not having the coating. A method of preparing a population of nanoparticles. The methods... Agent:

20150037262 - Device for the transplantation of cells in suspension: The invention relates to a device (1) for the transplantation of cells (3) in suspension comprising a support with at least one micro-cavity (2) containing or able to contain said suspension in direct contact with the object on which the cells are to be transplanted. The device is intended for... Agent:

20150037263 - Treatment of multiple sclerosis with combination of laquinimod and fingolimod: This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with fingolimod. This invention also provides a package and a pharmaceutical composition comprising laquinimod and fingolimod for... Agent: Teva Pharmaceutical Industries, Ltd.

20150037264 - Anhydrous antiperspirant compositions: An antiperspirant composition comprising a suspension of from 1 to 50% of an aluminium and/or zirconium containing antiperspirant active, a carrier substance in which the antiperspirant active is insoluble, and a poly(ethylene glycol) solution of a polyelectrolyte salt comprising sodium, potassium, magnesium, calcium, chloride and bromide ions, the weight ratio... Agent: Conopco, Inc., D/b/a Unilever

20150037265 - Oral hygiene products and method of using the same: A composition for highly efficient and quick plaque and tartar removal and inhibition including pure ascorbic acid crystals and/or granulars (vitamin C) and an enamel repairing composition such as hydroxyapatite. The composition can contain from about 10% up to 90% of ascorbic acid without compromising the integrity of tooth enamel... Agent: Dentech, Inc.

20150037266 - Oral care whitening compositions: Described herein are whitening compositions comprised of a peroxide component, and an adhesion system, which effectively provide whitening using a remarkably low level of peroxide. Methods of making and using these compositions are also described herein.... Agent: Colgate-palmolive Company

20150037267 - Personal care composition: The present invention relates to a personal care composition for topical application having skin lightening application. It is an object of the present invention to provide for a personal care composition that comprises fractions obtained from natural sources that gives enhanced skin lightening as compared to known fractions from natural... Agent: Conopco., Inc., D/b/a Unilever

20150037268 - Niacin-peptide having skin whitening activity and use for same: Provided is niacin-peptide which has skin whitening activity. The peptide of the present invention has skin whitening activity by inhibiting melanogenesis, that is, by inhibiting the expression of a gene related to melanogenesis (for example, TRP-1, TRP2, or MIFT). The peptide of the present invention has high stability and skin... Agent:

20150037269 - Topical compositions for treatment of excessive sweating and methods of use thereof: The present invention provides for 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane and a pharmaceutically acceptable anion thereof for use in the topical treatment or prophylaxis of excessive sweating, and compositions containing these ingredients.... Agent:

20150037270 - Compositions and kits for hair and skin: Compositions, kits, and methods for repairing bonds, for example, disulfide bonds, in hair or on the skin are disclosed. The compositions provide improved conditioning benefit for dry hair or moisturize the skin. The compositions also provide a long lasting moisturized feel and smooth feel to the skin or hair, without... Agent: Liqwd, Inc.

20150037272 - Organopolysiloxane emulsion composition: An organopolysiloxane emulsion composition produced by the emulsion polymerization of an emulsion that comprises (A) an organopolysiloxane containing a silanol group or an organooxy group, (B) a nonionic surfactant represented by formula (2): R2O(EO)a(PO)bR3 (wherein R2 represents an alkyl group or R4(CO)—; R4 represents an alkyl group; R3 represents an... Agent:

20150037273 - Low viscosity polyorganosiloxanes comprising quaternary ammonium groups, methods for the production and the use thereof: Low viscosity polyorganosiloxanes comprising a) at least one polyorganosiloxane group, b) at least one quaternary ammonium group, c) at least one terminal ester group, methods of the manufacture thereof and their use for the modification of surfaces of substrates.... Agent:

20150037271 - Methods for fixing hair and skin: Compositions, kits, and methods for repairing bonds, for example, disulfide bonds, in hair or on the skin are disclosed. The compositions provide improved conditioning benefit for dry hair or moisturize the skin. The compositions also provide a long lasting moisturized feel and smooth feel to the skin or hair, without... Agent: Liqwd, Inc.

20150037274 - Methods of filtering multiple contaminants, mitigating contaminant formation, and recycling greenhouse gases using a humic and fulvic reagent: A highy alkalized humic and fulvic filter reagent for the removal of multiple contaminants from a gas is provided. The contaminants removed from the gas stream may include, but are not limited to, Carbon Dioxide, Sulfur Oxide, Nitrogen Oxides, Hydrogen Sulfides, radionuclides, mercaptans, ammonia, toxic metals, particulates, volatile vapors, and... Agent: Arctech, Inc.

20150037275 - Rifaximin complexes: There is provided a complex comprising rifaximin and a complexing agent, wherein the complexing agent is a polyvinyl pyrrolidone (PVP) or a cyclodextrin. There is also provided a process for preparing the complex, a pharmaceutical composition including the complex and therapeutic uses of the complex.... Agent:

20150037276 - Hydrocolloid composition and an article containing the same: The present invention provides a hydrocolloid composition which, based on 100% by weight of the hydrocolloid composition, comprises: 10-90%) by weight of a polyisobutylene tackifier; 5-55% by weight of a hydrophilic absorbing substance; and 0.1-20% by weight of a functional ingredient. The invention further provides an article containing the hydrocolloid... Agent: 3m Innovative Properties Company

20150037278 - Initial relative lymphocyte count as predictive biomarker: The invention relates to a method for predicting an improved therapeutic benefit for an individual with a tumor load before initiating an immune therapy which is capable of activating immune cells against said tumor as well as to pharmaceutical compositions for use in this method.... Agent: Markus Heiss

20150037277 - Methods of reducing salmonella in poultry: Described herein are methods of reducing Salmonella in the intestines of poultry in need thereof by administering to a poultry bird an effective amount of an interleukin-10 peptide or an isolated antibody that specifically binds an interleukin-10 peptide. Administering may be performed within 1 to 4 weeks of harvest of... Agent:

20150037279 - Sustained release formulation of interleukin-10 for wound treatment and related methods: A sustained release formulation of interleukin-10 for wound treatment and related methods is provided.... Agent:

20150037280 - Substituted pyrazolone compounds and methods of use: The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the... Agent: Calitor Sciences, LLC

20150037283 - Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases: Disclosed are compositions and methods comprising combinations of anti-CD74 antibodies with a therapeutic agent that is attached to the anti-CD74 antibody or separately administered. Preferably, the therapeutic agent is an antibody that binds to an antigen different from CD74, such as CD19, CD20, CD21, CD22, CD23, CD37, CD40, CD40L, CD52,... Agent:

20150037282 - D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease: s

20150037281 - Variants of prothymosin alpha and methods of using same: The present invention relates to novel Prothymosin Alpha (ProTα) variants that are capable of inducing cell-mediated immune responses. These variants lack a nuclear localization signal and the proliferative oncogenic activity previously attributed to ProTα. The variants of the invention are used in methods of treating, for example, viral infections, bacterial... Agent: Icahn School Of Medicine At Mount Sinai

20150037284 - Novel listeria bacteriophage p825 and uses thereof: The present invention relates to a novel Listeria bacteriophage designated ProCC P825. In particular, the present invention relates to the endolysin PlyP825 encoded by the novel phage ProCC P825 and uses of the novel endolysin PlyP825 for controlling Listeria contamination and infection.... Agent: DsmIPAssets B.v.

20150037296 - Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy: The present invention provides compositions comprising retroviral vectors, transduced cells, and methods of using the same for gene therapy. In particular, the present invention relates to lentiviral vectors and cells transduced with those vectors to provide gene therapy to subjects having an adrenoleukodystrophy and/or adrenomyeloneuropathy.... Agent: Bluebird Bio, Inc.

20150037299 - Generation of neural stem cells and motor neurons: A method of generating neural stem cells or motor neurons is disclosed, the method comprising up-regulating a level of at least one exogenous miRNA and/or down-regulating at least one miRNA using an agent which hybridizes to the miRNA in mesenchymal stem cells (MSCs) or down-regulating Related to testis-specific, vespid and... Agent:

20150037298 - Micrornas for the generation of astrocytes: A method of generating a population of cells useful for treating a nerve disease or disorder in a subject, the method comprising up-regulating a level of at least one exogenous miRNA in mesenchymal stem cells (MSCs) and/or down-regulating a level of at least one miRNA using a polynucleotide agent that... Agent:

20150037300 - Nucleic acid for treatment or prevention of immunodeficiency virus infection: A nucleic acid comprising a transcription regulation sequence whose transcription is induced by a trans-acting factor of a human immunodeficiency virus and a gene encoding a polypeptide having an endoribonuclease activity specific to single-stranded RNA, wherein the gene is located in such a position that the expression of the gene... Agent:

20150037301 - Recombinant factor viii having enhanced stability following mutation at the a1-c2 domain interface: The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having... Agent: University Of Rochester

20150037297 - Sickled erythrocytes and progenitors target cytotoxics to tumors: The present invention provides therapeutic mammalian cells which synthesize and express SS hemoglobin and a tumoricidal transgene. They are produced by transduction of SS erythroid progenitors/erythroblasts using viral vectors comprising a tumoricidal transgene operatively linked to the coding region of SS β-globin promoter/enhancer. Such transduced SS erythroid cells differentiate into... Agent:

20150037285 - Methods for efficient transfer of viable and bioactive microbiota: The present invention relates to methods for transferring gastrointestinal microbiota that preserves viability and bioactivity of the microbiota, even if fastidious, anaerobic, and non-culturable organisms are present. Also provided herein are examples of how manipulating the gastrointestinal microbiota and introducing particular taxa can be used to affect host metabolic status... Agent: New York University

20150037286 - Use of roseburia in the prevention and treatment for obesity related diseases: The present invention provides use of Roseburia in the preparation of composition for prevention and/or treatment of obesity related diseases. Also provided are a composition used in the treatment and prevention for obesity related diseases, comprising pharmaceutical, drink, food, and/or animal feed composition, etc; and a method of reducing body... Agent:

20150037302 - Method of producing biosurfactants: The present invention relates to a method of producing biosurfactants, such as surfactin, comprising culturing at least one biosurfactant-producing microbe in a liquid culture medium comprising vinasse as a carbon source. Methods of using the crude biosurfactant containing culture broth in tertiary oil recovery and as antibacterial compositions in tertiary... Agent:

20150037306 - Adjuvant containing polyorganosiloxane and organic solvent for preparing a larvicidal tank mix: The present invention relates to a method for controlling insects comprising the steps of preparing a tankmix by mixing a larvicide and a liquid adjuvant, wherein the adjuvant is essentially free of the larvicide and contains at least 1 wt % polyorganosiloxane, and at least 20 wt % synthetic organic... Agent: Basf Se

20150037307 - Poultry farm practices: The present invention relates to methods of improving the environment within a poultry farming facility including reducing ammonia production in a poultry facility, inhibiting urease enzymes in poultry litter, reducing levels of pathogenic bacteria in poultry litter, improving productivity of poultry farms, reducing or preventing pododermatitis in poultry reared in... Agent:

20150037287 - Method of treating a malignancy in a subject and a pharmaceutical composition for use in same: There is a disclosed a method of killing abnormal cells such as malignant cells including melanoma cells, using a virus recognising at least one of a cell adhesion molecule and a complement regulatory protein. The virus may be a member of the Picornaviridae family. Coxsackie A-group viruses have been found... Agent: Viralytics Limited

20150037288 - Methods for increasing the infectivity of viruses: Methods of using viruses labeled with alkyne-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to increase the infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling... Agent:

20150037289 - Activating adipose-derived stem cells for transplantation: A method of preparing a stem cell preparation is provided. The method includes steps of collecting adipose tissue from a mammal, contacting that adipose tissue with an enzyme preparation to digest fat and connective tissue and preserve stem cells and collecting those stem cells. In addition a kit is provided... Agent:

20150037291 - Compositions and methods for cell transplantation: The present invention relates to compositions and methods for cell transplantation. In particular, the present invention provides a composition comprising procoagulant cells and at least one factor Xa inhibitor, preferably rivaroxaban, as well as at least one thrombin inhibitor, preferably bivalirudin.... Agent: Universite Catholique De Louvain

20150037294 - Methods for promoting wound healing and muscle regeneration with the cell signaling protein nell1: The present invention provides methods for promoting wound healing and treating muscle atrophy in a mammal in need. The method comprises administering to the mammal a Nell1 protein or a Nell1 nucleic acid molecule.... Agent:

20150037295 - Methods of inducing tissue regeneration: Methods are provided for producing cells within a lineage (lineage restricted cells) from post-mitotic differentiated cells of the same lineage ex vivo and in vivo, and for treating a subject in need of tissue regeneration therapy by employing these lineage-restricted cells. In addition, the production of lineage restricted cells from... Agent:

20150037290 - Methods of modulating smooth muscle cell proliferation and differentiation: The present disclosure provides methods of inducing smooth muscle cell differentiation. The present disclosure provides genetically modified cells comprising exogenous miR-143 and/or miR-145 nucleic acids; and artificial tissues comprising the genetically modified cells. The present disclosure provides methods and compositions for reducing pathological angiogenesis. The present disclosure provides methods of... Agent: The J. David Gladstone Institutes

20150037292 - Stromal stem cells: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface... Agent: Orbsen Therapeutics Limited

20150037293 - Technologies for pancreatic islet transplantation: Biocompatible nanomatrices composed of peptide amphiphiles are provided for the embedding of cell populations for their implantation into a recipient animal or human. To confine the nanomatrix to a site of implantation, the nanomatrix can be encapsulated in a nanofiber sack formed from an electrospun nanofiber sheet. The nanofiber sheets... Agent:

20150037303 - Cells, compositions, and treatment methods for stimulation of hematopoiesis: The invention discloses novel methods, compositions of matter, and kits for the treatment of disorders affecting the hematopoietic system. Patients are administered an autologous cellular mixture derived from adipose stromal vascular fraction, said cellular mixture comprising endothelial cells, endothelial progenitor cells, T regulatory cells, monocytes, and hematopoietic stem cells. In... Agent: Regen Biopharma, Inc

20150037304 - Methods and compositions for modification of hla: Disclosed herein are methods and compositions for modulating the expression of a HLA locus, including cells that lack expression of one or more classic HLA genes but are not targeted by Natural Killer (NK) cells for lysis.... Agent:

20150037305 - Systems, methods, and apparatus for resuspending cells from surgical laundry: Systems, apparatus, methods, and articles of manufacture provide for resuspending and/or collecting blood or other types of cells from used surgical sponges and/or other types of surgical articles.... Agent:

20150037309 - Preparation for improving the action of receptors: s

20150037308 - Pyrroloquinoline quinone alcohol adduct:

20150037310 - Biopesticide compositions comprising water soluble polyols: Provided are liquid compositions comprising inactive biopesticide precursors comprising a glucosinolate concentrate, a plant material comprising a myrosinase enzyme complex, and a water soluble polyol. Further provided are methods of making and using such compositions.... Agent:

20150037312 - Binding proteins to the constant region of immunoglobulin g: The present invention provides polypeptides that bind to immunoglobulin G and methods for their use.... Agent:

20150037311 - Targeted lysosomal enzyme compounds: The present invention is related to a compound that includes a lysosomal enzyme and a targeting moiety, for example, where compound is a fusion protein including iduronate-2-sulfatase and Angiopep-2. In certain embodiments, these compounds, owning to the presence of the targeting moiety can crossing the blood-brain barrier or accumulate in... Agent: Angiochem Inc.

20150037313 - Mixture of peptide-bound tryptophan and polypeptide-bound tryptophan: The present invention relates to a composition which comprises tryptophan whereby 10 to 90%, preferably 20 to 80% of the tryptophan is present as free tryptophan or peptide-bound tryptophan and 10 to 90%, preferably 20 to 80% of the tryptophan is present as polypeptide-bound tryptophan.... Agent:

20150037314 - Dry haemostatic composition: Disclosed is a dry composition, which upon addition of an aqueous medium forms a substantially homogenous paste suitable for use in haemostasis procedures. The paste forms spontaneously upon addition of the liquid, hence no mechanical mixing is required for said paste to form. Further disclosed are methods of preparing said... Agent:

20150037315 - Dietary supplement: The present invention relates to a dietary supplement and methods of use thereof. More particularly, the invention relates to a composition including a kiwifruit extract in combination with an amylase inhibitor and/or a bifunctional protease-amylase inhibitor, particularly, but not exclusively, for managing gut health or for the treatment or prevention... Agent: Vital Food Processors Limited

20150037317 - Method for selecting a pool of molecules: The present disclosure relates to a method for selecting a pool of molecules comprising detecting if the pool of molecules has binding specificity to an agent. A method for selecting a pool of biological markers in or on a cell, a composition comprising a pool of molecules, a method for... Agent:

20150037316 - Placental stem cell populations: The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting.... Agent:

20150037318 - Treatment of multiple sclerosis with combination of laquinimod and flupirtine: This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with flupirtine. This invention also provides a package and a pharmaceutical composition comprising laquinimod and flupirtine for... Agent: Teva Pharmaceutical Industries, Ltd.

20150037328 - Anti-cxcr4 antibodies and antibody-drug conjugates: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates... Agent:

20150037324 - Antibodies and methods of treating cancer: Described herein are antibodies against GPR49 and uses of such antibodies. Various aspects relate to monoclonal, humanized, or fully human antibodies against GPR49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies, and methods of treating cancer with such antibodies.... Agent:

20150037330 - Histamine-releasing factor (hrf), hrf-receptor and methods of modulating inflammation: Methods of treating a food allergy, allergic reactions, hypersensitivity, inflammatory responses, inflammation are provided. In one method, histamine releasing factor (HRF)/translationally controlled tumor protein (TCTP) is contacted with a compound that inhibits or reduces binding of HRF/TCTP to an immunoglobulin in order to treat the food allergy, allergic reaction, hypersensitivity,... Agent: La Jolla Institute For Allergy And Immunology

20150037323 - Humanized axl antibodies: The present invention refers to monoclonal humanized antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.... Agent: U3 Pharma Gmbh

20150037331 - Il-31 monoclonal antibodies: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by... Agent: Zymogenetics, Inc.

20150037319 - Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration: The present invention provides a method for preparing a composition comprising highly concentrated antibodies by ultrafiltration in batch concentration mode having a first constant feed rate step and a second controlled feed rate step.... Agent: Chugai Seiyaku Kabushiki Kaisha

20150037329 - Method of reducing titers of antibodies specific for a therapeutic agent: The present invention relates, in general, to a method of treating patients undergoing enzyme replacement therapy (ERT) or other therapy involving the administration of a proteinaceous therapeutic agent as well gene replacement therapy with non-viral or viral vectors, or other therapeutic modality or modalities, used alone or in combination, which... Agent: Duke University

20150037321 - Methods and compositions for inhibiting cd32b expressing cells: The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.... Agent:

20150037322 - Methods and compositions for inhibiting cd32b expressing cells: The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.... Agent:

20150037327 - Mirna based treatment monitoring in multiple sclerosis: The present invention relates to methods of determining whether a patient responds to a therapeutic treatment of multiple sclerosis (MS), of monitoring the course of multiple sclerosis (MS) in a patient, of determining the risk for a relapse of multiple sclerosis (MS) in a patient, and of adjusting the dose... Agent:

20150037326 - Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen: The present invention is directed to a pharmaceutical composition including (eg for use as an adjuvant) a polymeric carrier cargo complex, comprising as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components and as a cargo at least one nucleic acid (molecule) and at least one antigen associated with... Agent: Curevac Gmbh

20150037325 - Slit-robo signaling for diagnosis and treatment of kidney disease: Provided herein are methods for the treatment of chronic kidney disease and proteinuria and for the diagnosis of chronic kidney disease and monitoring the effects of treatment on the progression of chronic kidney disease and proteinuria based on unexpected roles for the SLIT-ROBO signaling pathway in the regulation of podocyte... Agent:

20150037320 - Treatment of macrophage-related disorders: The present invention provides a method of treating a macrophage related disease comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The present invention also provides a method of modulating macrophage accumulation or activation comprising administering to a subject in... Agent: The Regents Of The University Of California

20150037332 - Treatment of metastic breast cancer: The present invention concerns treatment of previously untreated HER2-positive metastatic breast cancer with a combination of a growth inhibitory HER2 antibody, a HER2 dimerization inhibitor antibody and a taxane. In particular, the invention concerns the treatment of HER2-positive metastatic breast cancer in patients who did not receive prior chemotherapy or... Agent: Genentech, Inc.

20150037334 - Long life polypeptide binding molecules: The present invention relates to a binding molecule comprising at least three domains comprised in at least one polypeptide chain, wherein the first binding domain is a binding domain which is capable of binding to a cell surface molecule on a target cell, the second binding domain is a binding... Agent:

20150037335 - Therapeutic use of p75ntr neurotrophin binding protein: The present invention relates to a p75NTR neurotrophin binding protein, p75NTR(NBP), for use in the treatment of pain and/or a symptom of pain.... Agent:

20150037333 - Tumour necrosis factor receptor fusion proteins and methods of using the same: A chimeric fusion polypeptide is provided comprising an extracellular domain of a canine TNF receptor p60 or p80 polypeptide conjoined to an Fc region of a canine IgG immunoglobulin heavy chain. The chimeric fusion polypeptide may be used in the treatment or prevention of conditions in canines mediated by TNF... Agent: Nvip Pty Ltd

20150037336 - Combination of hb-egf binding protein and egfr inhibitor: The present application relates to the combined use of an antigen-binding protein that binds HB-EGF and an EGFR tyrosine kinase inhibitor in medical treatment.... Agent: U3 Pharma Gmbh

20150037338 - Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders: The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides, to methods for preparing such amino acid sequences and polypeptides, to host cells expressing or capable of expressing such amino acid sequences or polypeptides, to compositions, and in particular to pharmaceutical compositions, that comprise such amino... Agent: Ablynx N.v.

20150037339 - Anti-activin a antibodies and uses thereof: The present invention provides antibodies that bind to Activin A and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Activin A with high affinity. The antibodies of the invention are useful for the treatment of diseases and... Agent:

20150037337 - Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics: The invention provides improved non-human vertebrates and non-vertebrate cells capable of expressing antibodies comprising human variable region sequences. The present invention is directed to the provision of long HCDR3s from non-human vertebrates and cells. The present invention is also directed to the provision of novel V, D and J pairings... Agent: Kymab Limited

20150037340 - Novel antigen binding protein and its use as addressing product for the treatment of cancer: The present invention relates to an antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect, the invention relates to an antigen binding protein, or antigen binding fragments,... Agent:

20150037343 - Angiopoietin-2 specific antibodies and uses thereof: An Ang2 specific antibody, a method of inhibiting angiogenesis or a method of treating a disease related to the activation and/or overproduction of Ang2 using the antibody, and a composition for diagnosing a disease related to the activation and/or overproduction of Ang2 including the antibody.... Agent:

20150037341 - Diagnostic and therapeutic method: The present invention relates to a method of treating or preventing transthyretin amyloidosis, pharmaceutical composition for use in said treatment or prevention, as well as to a diagnostic method and a kit.... Agent: Plysackaridforskning I Uppsala Ab

20150037345 - Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and... Agent:

20150037342 - Method to prevent cancer metastasis and inhibit inflammation by inhibition of p68 interaction with calmodulin: Compositions and methods for inhibiting cancer cell metastasis and inflammation are disclosed. The methods generally involve administering to a subject a composition containing an agent that selectively inhibits the binding of p68 RNA helicase to calmodulin (CaM) in the cells.... Agent: Proda Biotech LLC

20150037344 - Therapeutic agent: The present invention relates to agents which modulate the effect of a RAMP (Receptor Activity Modifying Protein) protein on a Calcitonin Receptor Like Receptor (CRLR). Also included in the present invention are methods and uses of such agents and assays for identifying such agents. The agents of the present disclosure... Agent:

20150037346 - Prediction of responsiveness to treatment with immunomodulatory therapeutics and method of monitoring abscopal effects during such treatment: Efficacy of a therapeutic to enhance antitumor immunity in a patient is predicted, where the therapeutic is one that targets an immunomodulatory leukocyte membrane protein (ILMP) to enhance immune activity. Peripheral blood sample from the patient is tested for levels of monocytes having specific cell surface markers (CD14+, HLA-DRlow) prior... Agent: Sloan-kettering Institute For Cancer Research

20150037347 - Method of treating a pathological syndrome and a pharmaceutical agent: Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a... Agent:

20150037349 - Anti-tumor necrosis factor-alpha agents and uses thereof: The present invention relates to polypeptides comprising one or more antibody single domains, or antigen-binding fragments thereof, directed against Tumor Necrosis Factor-alpha, in particular, two light chain variable domains in dimeric form, where the dimer has high solubility. It also relates to methods of using anti-Tumor Necrosis Factor-alpha polypeptides in... Agent:

20150037348 - Human antibodies that bind human il-12 and methods for producing: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody... Agent:

20150037350 - Negative modulator of hedgehog signalling for use in treating th2-mediated diseases: The invention provides means for treating Th1- and Th2-mediated diseases, such as asthma, allergic dermatitis and Th2-driven cancer. The invention extends to pharmaceutical compositions for use in treating such conditions, and to methods of treatment. The invention also extends to adjuvants and vaccines per se, and to their use in... Agent: Ucl Business PLC

20150037351 - Novel therapeutic target for the prevention of tumour metastasis: The present invention relates to an inhibitor of the P2Y2 receptor or an inhibitor of the P2Y2 receptor signaling pathway for use in preventing the metastasis of tumours or as a lead compound for developing a drug for preventing the metastasis of tumours.... Agent:

20150037352 - Novel ha binding agents: This disclosure relates to novel peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use.... Agent:

20150037354 - Combination therapies including inhibitors of the extracellular domain of e-cadherin: The present invention is based on our work with E-cadherin, including soluble portions of this integral membrane glycoprotein. The compositions of the present invention include therapeutically effective amounts of a first agent that targets epitopes within one or more of the EC2-EC5 subdomains of the ectodomain of E-cadherin (including these... Agent:

20150037353 - Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2: The present invention relates to a method for identifying a subject at risk of developing hypertensive end organ damage, such as and in particular heart failure, comprising: a) obtaining a biological sample of said subject; b) determining the level of at least one non-myocytal marker in said sample; c) comparing... Agent:

20150037356 - Anti-siglec-15 antibodies and uses thereof: This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia.... Agent: Medimmune Limited

20150037358 - Composition and methods for treating cancer: Compositions and methods for detecting, prognosing, inhibiting, treating, and/or preventing cancer are provided.... Agent:

20150037355 - Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that... Agent: Jennerex Inc.

20150037357 - Immune stimulation/metabolic inhibition as antitumor therapy: Methods, compositions and compounds that include a nucleic acid comprising a sequence consisting essentially of polyT/polyU and an agent that inhibits the production or activity of an immunosuppressive compound for treating tumors are described.... Agent:

20150037359 - Xten conjugate compositions and methods of making same: The present invention relates to extended recombinant polypeptide (XTEN) compositions, conjugate compositions comprising XTEN and XTEN linked to cross-linkers useful for conjugation to pharmacologically active payloads, methods of making highly purified XTEN, methods of making XTEN-linker and XTEN-payload conjugates, and methods of using the XTEN-cross-linker and XTEN-payload compositions.... Agent: Amunix Operating, Inc.

20150037360 - Lysosome-cleavable linker: The present invention relates to a linker for forming conjugates of a protein or peptide with a therapeutically active agent and which comprise a thiomaleamic acid moiety that is susceptible to cleavage under the pH conditions prevalent in the lysosome.... Agent:

20150037361 - Compositions and methods to treat the bihormonal disorder in diabetes: The described invention provides methods and compositions for treating diabetes and hyperglycemia in a mammal comprising administering to the mammal a therapeutic amount of a glucagon depleting compound. Also provided are methods and compositions for eliciting a bihormonal response in a mammal comprising administering to the mammal a therapeutic amount... Agent:

20150037362 - Modulators of antiviral signaling pathways and therapeutic uses thereof: The invention provides methods, compositions, and kits featuring novel RIG-I like receptor activators or inhibitors for use in preventing or treating virus infection or autoimmune disease.... Agent: Children's Medical Center Corporation

20150037363 - Recombinant t-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction: Methods are provided for the treatment of subjects with cognitive or neuropsychiatric impairment induced by substance addiction and for increasing cognitive function in a subject with substance addiction. In some embodiments, the methods include administering to the subject a therapeutically effective amount of a major histocompatibility complex (MHC) molecule including... Agent: The United States Government As Represented By The Department Of Veterans Affairs

20150037364 - Adenoviruses and their use: Baboon Adenovirus (BaAdV)-2/4 and BaAdV-3 are disclosed herein. BaAdV-2/4 and BaAdV-3 polynucleotide, polypeptides and antibodies that specifically bind BaAdV-2/4 and/or BaAdV-3 are disclosed. Methods are disclosed for detecting BaAdV-2/4 and BaAdV-3. Methods are also disclosed for treating, preventing, and inducing an immune response to BaAdV-2/4 and/or BaAdV-3. Kits are also... Agent:

20150037366 - Method for treating inflammation: A method for reducing or alleviating inflammation in a subject includes administering to the subject a therapeutically effective amount of: (a) Ac-TMP-1 or a biologically active fragment or variant of Ac-TMP-1; (b) Ac-TMP-2 or a biologically active fragment or variant of Ac-TMP-2; or (c) a combination of (a) and (b),... Agent: James Cook University

20150037365 - Novel malaria vaccine: (In the formula, X1 represents the 1st to 7th amino acid residues in a polypeptide set forth in SEQ ID NO: 1; X2 represents the 73th to 177th amino acid residues; X3 represents the 178th to 258th amino acid residues; X4 represents the 259th to 289th amino acid residues; X5... Agent:

20150037367 - Methods and compositions of protein antigens for the diagnosis and treatment of herpes simplex viruses type 1 and 2: Contemplated compositions, devices, and methods are drawn to various antigens from Herpes Simplex Virus type 1 (HSV-1) and Herpes Simplex Virus type 2 (HSV-2) and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities... Agent:

20150037368 - Polyanionic polymer adjuvants for haemophilus influenzae b saccharide vaccines: The present invention relates to methods of reducing flocculation in an immunogenic composition, where said immunogenic composition comprises (a) Haemophilus influenzae B capsular polysaccharide or oligosaccharide (PRP) and (b) at least one non-PRP antigen. The invention further relates to kits comprising (i) a first composition comprising a Haemophilus influenzae B... Agent:

20150037369 - Methods of transforming a listeria: Site-specific Listeria integration vectors and methods for their use are provided. The subject vectors include a bacteriophage integrase gene and a bacteriophage attachment site, where in many embodiments the bacteriophage that is the source 0 of these elements is a listeriophage. In certain embodiments, the subject vectors further include a... Agent:

20150037370 - Diatom-based vaccines: This invention provides diatom-based vaccines.... Agent: The Regents Of The University Of California

20150037371 - Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens: The invention provides a method of enhancing the immunogenicity of pathogenic antigens by removing or disrupting intrachain disulfide bonds responsible for maintaining tertiary protein structure. Removal of one or more disulfide bonds can increase the titer of neutralizing antibodies to a pathogen (e.g., a bacterium, fungus, virus, or parasite). The... Agent:

20150037372 - Ph-responsive high-density lipoprotein-like particle complex: The present invention relates to a high-density lipoprotein (HDL)-like particle composite which is a drug-encapsulating apoA-I comprising apoA-I and a drug encapsulated in the apoA-I capable of releasing the drug encapsulated in the apoA-I under acidic pH conditions, and a preparation method thereof. Since the HDL-like particle composite of the... Agent: Research & Business Foundation Sungkyunkwan University

20150037373 - Method of enhancing the proliferative phase of a primary t cell response: Disclosed is an alkaline extract of shredded pinecones yields a polyphenylpropanoid polysaccharide complex (PPC) that functions as an orally active immune adjuvant. Specifically, the oral PPC boosts the number of antigen-specific memory CD8+ T cells generated in response to a variety of vaccine types (DNA, protein, and dendritic cell) and... Agent: Tampa Bay Research Institute

20150037374 - Anti-tumor compositions and uses thereof: The present invention provides a composition for raising an immune response against a tumor. The composition comprises at least one tumor antigen, a saponin-based adjuvant, a TLR ligand and a Flt3 ligand.... Agent:

20150037378 - Anti-microbial formulations containing nitric oxide: Compositions and methods are directed to antimicrobial compositions and articles that release .NO from the composition and/or article in an amount effective to act as a microbicide. Preferred .NO-releasing compositions include a nitrosyl-containing organometallic compound, and can be encapsulated in gels or topical coatings.... Agent:

20150037375 - Doping agents and polymeric compositions thereof for controlled drug delivery: Provided herein are 3-dimensional drug-eluting materials comprising biodegradable polymer(s), one or more bioactive agents and entrapped air. Various embodiments of the methods and compositions described herein are based, in part, on the discovery of hydrophobic doping agents that can be used in the manufacture of polymeric drug delivery compositions that... Agent: Trustees Of Boston University Et Al

20150037376 - Methods and compositions for oral administration of melanocortin receptor agonist compounds: Methods and compositions for oral administration of melanocortin receptor agonist compounds are disclosed herein. Methods and compositions for oral administration of melanocortin receptor agonist compounds are provided for treatment of sexual dysfunction, including male sexual dysfunction and female sexual dysfunction. Methods and compositions for oral administration of melanocortin receptor agonist... Agent:

20150037377 - Substituted cellulose acetates and uses thereof: The present invention relates to substituted cellulose acetates and methods of use thereof. One embodiment of the present invention provides a coating having a substituted cellulose acetate having a polar substituent that has an oxygen atom covalently bonded to a nonmetal selected from the group of sulfur, phosphorus, and boron;... Agent: Celanese Acetate LLC

20150037380 - Applied films for smoothing wrinkles and skin texture imperfections: A skin smoothing film made from a skin smoothing composition that comprises sodium silicate, polyvalent silicate and water. Moreover, the film may be made from a composition that has a contraction value of from about 30% to about 160%. The film thickness is from about 5 microns to about 50... Agent:

20150037379 - Cosmetic compositions: The present invention relates to a composition for topical application comprising in a physiologically acceptable medium at least a benzotriazol derivative, a microfine metal oxide particle, a cosmetic solvent selected from the group of benzoate solvents such as phenethyl benzoate and a phosphate ester emulsifier. More specifically, the invention relates... Agent: DsmIPAssets B.v.

20150037383 - Leave-on compositions containing cellulose materials: The compositions and methods of this invention relate to a leave-on skin care composition containing hydrophobic, linear cellulose particles having an average length of from about 1 to about 500 μm, a particle aspect ratio from about 2 to about 25 and an average thickness of from about 1 to... Agent:

20150037382 - Microsphere skin treatment: This application provides a microsphere suitable for tissue engineering that comprises connective tissue growth factor (CTGF). Also provided is a matrix, material or scaffold suitable for tissue engineering that comprises connective tissue growth factor (CTGF) and basic fibroblast growth factor (bFGF). Additionally, methods of treating skin of a human are... Agent: The Trustees Of Columbia University In The City Of New York

20150037381 - Silicon dioxide in shaving products: The invention is a shaving formulation comprising 0.3 to 5% by weight of noncrystalline amorphous silicon dioxide SiO2 which has not been produced pyrogenically, having a particle size of 2 to 30 μm.... Agent:

20150037384 - Antibacterial materials including water-absorbent and water-resistant properties, and methods of manufacturing the same: A material includes a bamboo-based, water-absorbent fabric layer defining an exposed first surface and a second, opposite surface. A water-resistant, antibacterial coating layer covers the second surface of the fabric layer. The material is both water-absorbent and water-resistant, comfortable, recyclable, sanitary, machine washable, drier safe, and environmentally friendly. Such material... Agent:

20150037385 - Ceramic-containing bioactive inks and printing methods for tissue engineering applications: Ink formulations comprising bioactive particles, methods of printing the inks into three-dimensional (3D) structures, and methods of making the inks are provided. Also provided are objects, such as tissue growth scaffolds and artificial bone, made from the inks, methods of forming the objects using 3D printing techniques, and method for... Agent:

20150037387 - Biomatrix composition and methods of biomatrix seeding: Apparatus and methods are described for generating autologous tissue grafts, the apparatus including a point of care SVF isolation unit that includes a tissue digestion chamber in fluid communication with a lipid separating chamber, whereby SVF cells are isolated without centrifugation; and a cell seeding chamber in fluid communication with... Agent: Ingeneron, Inc.

20150037386 - Compositions and methods for promoting bone formation: A method for promoting bone formation is provided. More specifically, a method for promoting bone formation by promoting osteoclast formation is provided. In one embodiment, an implant comprising an implantable material and an osteoclast stimulating substance is provided.... Agent: Warsaw Orthopedic, Inc.

20150037389 - Edible product comprising reconstituted plant material: The present invention relates to an edible product, which comprises a fibrous plant product and a plant extract applied thereto. Further, the invention relates to a corresponding method for producing said edible product and its use in at least one of food, food supplement, medicinal, cosmetic, well-being, nutraceutical or phytotherapeutical... Agent:

20150037388 - Edible slow dissolving film for treating oral ulcerations: The invention relates, in one aspect, to a mucoadhesive edible slow dissolving film comprising a salt of alginic acid, an edible cellulose derivative, an edible protein, and edible polymer delaying the dissolution in a physiological fluid of the edible film selected from polyvinylpyrrolidone, a carboxyvinyl polymer and mixtures thereof, in... Agent:

20150037391 - Local administration of gallium compositions to treat pain: Provided are methods of treating pain, including neuropathic pain, in human and veterinary individuals. These methods employ locally administrable pharmaceutical gallium compositions, including pharmaceutical gallium compositions suitable for administration to the skin and mucous membranes. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate or gallium nitrate, together... Agent:

20150037390 - Self-assembling bis-urea compounds for drug delivery: Cationic, anionic, and/or zwitterionic bis-urea compounds self-assemble by non-covalent interactions in aqueous solution to form high aspect ratio nanofibers. The nanofibers reversibly bind drugs by non-covalent interactions, forming drug compositions for exhibiting sustained release of the drug.... Agent: International Business Machines Corporation

20150037392 - Liquid-permeable primary dressing having a fraction of heavy metal: The present invention relates to a fluid-permeable primary dressing in strip form, having pores, perforations or honeycomb lattices, which enable the passage of fluid, further having a content of at least one heavy metal present in elemental or ionic form.... Agent:

20150037393 - Adhesive patches for use in sunless tanning: Adhesive patches for protecting skin imperfections such as age spots, from discoloring and/or darkening during sunless tanning are provided herein. The adhesive patches are sized and shaped to fully or partially cover the skin imperfections during application of a sunless tanning product such to provide a user with uniform color... Agent:

20150037394 - Drug delivery formulations: Mixtures of C1-12 compounds comprising at least one -Alk-O— group with thermogenic formulations, such as those comprising supercooled solutions of salts, are capable of substantial enhancement of transdermal drug delivery.... Agent: King's College London

20150037395 - Transdermal hormone delivery system: compositions and mtehods: A transdermal hormone delivery system (THDS) is disclosed. The THDS is useful for control of fertility and as therapy for a variety of diseases and conditions treatable by robust delivery of progestin and estrogen hormones, particularly the progestin, levonorgestrel. The THDS comprises a backing layer, an adjoining adhesive polymer matrix... Agent: Agile Therapeutics, Inc.

20150037400 - Cytotoxic agents: A method of killing a cell that is lacking in effective p53 protein activity, particularly as compared to wild type, is provided characterised in that it comprises delivering to the cell a single stranded DNA including a portion with at least one base, internally located with respect to any 3′... Agent:

20150037402 - Methods and compositions for treating gastric disorders: Improved efficacy in treatment of gastric disorders with botulinum toxin is obtained using liposomal encapsulated botulinum formulations for topical administration of the botulinum toxin. The liposomes are typically administered in a physiologically acceptable carrier such as saline or phosphate buffered saline by application onto the surface of the tissue within... Agent:

20150037404 - Methods for joint lubrication and cartilage wear prevention making use of glycerophospholipids: A method for lubricating a joint of a mammal by administering into a cavity of the joint a composition of liposomes that are multilamellar vesicles (MLV) dispersed in a fluid medium, the liposomes having a mean diameter of between about 0.8 μm to about 10 μm and including membranes of... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem

20150037398 - Molecule mixture comprising an amphipathic molecule type a, which has a positive total charge in the hydrophilic range, and an amphipathic molecule type b and a polyphenol c, method for producing said molecule mixture and use thereof: A molecule mixture comprising an amphipathic molecule of type A, which has an overall positive charge in the hydrophilic region, an amphipathic molecule of type B and a polyphenol C, the method for producing the molecule mixture, and the use thereof. The molecules of types A and B are present... Agent: Forschungszentrum J&#xdc Lich Gmbh

20150037399 - Novel use of pipoxolan and its pharmaceutical composition: The present disclosure concerns the novel use of pipoxolan and its pharmaceutical composition. Pipoxolan is useful therapeutic drugs for pathological conditions caused by vascular smooth muscle cell proliferation and migration to relieve a body appeared vascular injury, cerebrovascular ischemia, intimal hyperplasia, atherosclerotic stenosis, cerebral ischemia, and stroke.... Agent: China Medical University

20150037397 - Pharmaceutical compositions of pyridinium and quinolinium derivatives: The present invention relates to pharmaceutical compositions comprising a compound of formula (I) and a cyclodextrin or a liposome, to the process of preparing said compositions and their use for antitumor, antiviral, antiparasitic and antifungal treatment.... Agent: Traslational Cancer Drugs Pharma, S.l.

20150037401 - Sirna compositions and methods for inhibiting gene expression in tumor initiating cells of breast cancer: Disclosed are methods and compositions for siRNA-mediated therapy of mammalian diseases. In particular, compositions and methods are disclosed for treatment of therapy-resistant human breast cancers. In exemplary embodiments, siRNA molecules are presented that effectively knock down gene expression of one or more polynucleotides in breast cancer tumor initiating cells.... Agent:

20150037396 - Targeted delivery of anti-fungal agents: The present application discloses a targeting composition that actively targets chitin-like materials, such as those found in fungi, a drug delivery vehicle comprising a micelle that comprises the targeting composition and one or more anti-fungal drugs, and methods of using the drug delivery vehicle.... Agent:

20150037403 - Use of mir-23a-3p and/or mir-27a-3p mimics as therapeutic agents for inhibition of neuronal apoptosis following brain injury: The present invention relates to a method for treating a brain injury due to a traumatic event, disease or ischemic attack in a mammal subject, wherein the method comprises administering to the mammal subject an effective amount of miR-23a-3p and/or miR-27a-3p mimics to reduce activation of Puma, Noxa and Bax... Agent:

20150037405 - Pharmaceutical compositions of levodopa and carbidopa: The present invention relates to pharmaceutical compositions of levodopa and carbidopa. In particular, the invention relates to modified release pharmaceutical compositions of levodopa and carbidopa with at least one organic acidic excipient. The invention also relates to processes for the preparation of such compositions and use thereof for treatment of... Agent:

20150037408 - Delayed release pharmaceutical compositions of salsalate: The present invention relates to modified release pharmaceutical compositions comprising salsalate. The invention also relates to processes for the preparation of such compositions.... Agent:

20150037407 - Method to improve the safety of handling of high potency drugs in solid dosage forms without changing their efficacy: A method to improve the safety of handling of drug substances that are dispensed as solid oral dosage forms is described that does not alter the drug-release profile and the therapeutic efficacy of the pharmaceutical product.... Agent:

20150037406 - Novel crystalline form of sitagliptin sulfate: A novel crystalline form of sitagliptin sulfate is provided. In addition, a method for obtaining the crystalline form, pharmaceutical compositions comprising the novel crystalline form and the crystalline form for use as a medicament are provided.... Agent:

20150037409 - Controlled release hydrocodone formulations: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.... Agent:

20150037410 - Pharmaceutical compositions of ranolazine and dronedarone: The present disclosure relates to a solid composition comprising ranolazine and a spray-dried phosphoric acid salt of dronedarone in a bilayer tablet.... Agent: Gilead Sciences, Inc.

20150037411 - Tamper resistant dosage forms: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Agent: Purdue Pharma L.p.

20150037412 - Tamper resistant dosage forms: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Agent: Purdue Pharma L.p.

20150037413 - Tamper resistant dosage forms: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Agent: Purdue Pharma L.p.

20150037415 - Process for the preparation of a solid, orally administrable pharmaceutical composition: The present invention relates to a process for the preparation of a solid, orally administrable pharmaceutical composition, comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide in hydrophilized form, and its use for the prophylaxis and/or treatment of diseases.... Agent: Bayer Intellectual Property Gmbh

20150037414 - Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin: A controlled Release Pharmaceutical composition comprising an effective amount of Pravastatin and Fenofibrate, characterised in that the difference, in absolute value, between the times of maximal concentration (Tmax) of Pravastatin and Fenofibric acid is not less than 1.5 hours upon administration with food to humans.... Agent: Galephar M/f

20150037416 - Hemostatic device: A hemostatic device, method of making, and method of using for internal and external applications to wounds in the body of a patient to induce hemostasis at an anatomical site.... Agent:

20150037417 - Morphine polymer release system: A pharmaceutical composition for controlled release of an active substance is provided. The active substance is released into an aqueous medium by erosion of at least one surface of the composition. The composition comprises i) a matrix comprising a) polymer or a mixture of polymers, b) an active substance and,... Agent: Egalet Ltd.

20150037418 - Cosmetic composition: p

20150037419 - Functional pla-peg copolymers, the nanoparticles thereof, their preparation and use for targeted drug delivery and imaging: Functional PLA-PEG copolymers, the nanoparticles thereof, their preparation and use for targeted drug delivery and imaging The present invention concerns novel functional PEG-PLA containing copolymers, the nanoparticles containing the same, their process of preparation and their use for site specific targeted drug delivery and imaging.... Agent:

20150037420 - Sustained release formulation comprising octreotide and two or more polyactide-co-glycolide polymers: The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-co-glycolide polymers (PLGAs).... Agent: Novartis Ag

20150037421 - Arrdc1-mediated microvesicles (armms) and uses thereof: The invention provide isolated arrestin domain-containing protein 1 (ARRDC1)-mediated micro vesicles (ARMMs). Methods for generating and for isolating ARMMs are also provided herein. ARMMs can be used to deliver agents, for example, nucleic acids (e.g., siRNAs, microRNAs, lincRNAs), proteins (e.g., transcription factors, chromatin modulators, kinases, phosphorylases, or recombinases), or small... Agent: The Board Of Trustees Of The Leland Stanford Junioruniversity

20150037422 - Compositions and methods for ocular delivery of a therapeutic agent: Embodiments of various aspects described herein are directed to silk-based compositions for ocular delivery of at least one active agent, e.g., at least one therapeutic agent and methods of using the same. In some embodiments, the silk-based compositions can provide sustained release of at least one therapeutic agent to at... Agent:

20150037423 - Orally-disintegrating solid preparation: The present invention provides an orally-disintegrating solid preparation such as a tablet produced by tabletting fine granules showing controlled release of a pharmaceutically active ingredient and an additive, and the like, and the orally-disintegrating solid preparation containing fine granules coated with a coating layer containing a polymer affording a casting... Agent:

20150037424 - Sustained release oral solid preparation: A sustained release oral solid preparation comprising aripiprazole or a salt thereof and a sustained release excipient, the sustained release excipient comprising a gelling agent; at least one inert pharmaceutical diluent selected from the group consisting of monosaccharides, disaccharides, polyhydric alcohols, and mixtures thereof; and a pharmaceutically acceptable cationic cross-linking... Agent: Otsuka Pharmaceutical Co., Ltd.

20150037425 - Powder compositions for inhalation: The present invention relates to pharmaceutical powders for inhalation produced by a method consisting of a first step of mixing particles of a force-controlling agent selected from a salt of a fatty acid with particles of one or more pharmacologically active materials and a second step of sieving or blending... Agent:

20150037426 - Modified starch material of biocompatible hemostasis: A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves... Agent:

20150037427 - Nano delivery systems: The present invention makes use of a unique methodology of double nano-encapsulation for protecting and controlling the release of active agents, either hydrophobic or hydrophilic, from stable nanoparticles of opposite characteristics. The protection of the active agent was achieved by loading the agent to be protected, into nanocarriers, which were... Agent:

20150037429 - Controlled release microparticles: Formulations for controlled, sustained release of biologically active agents for the treatment of ocular disorders have been developed. These formulations are based on solid microparticles formed of the combination of biodegradable, synthetic polymers such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and copolymers thereof. The microparticles are characterized by low... Agent:

20150037428 - Geometrically engineered particles and methods for modulating macrophage or immune responses: Disclosed herein are geometrically engineered particles having varied shapes and sizes and surface charge which can incorporate drugs and/or other biomaterials for targeted delivery, such as pulmonary delivery. The size, shape, etc. of a particle can be designed and corresponding particles can be prepared that target or de-target immunological responses... Agent:

20150037430 - Formulation of a blood composition that is rich in platelet and/or growth factors and contains gelled proteins, and a method for its preparation: Formulation comprising, or derived from, an initial blood composition, wherein the formulation is rich in platelets and/or growth factors and proteins originating from the initial blood composition, and wherein the proteins are in a gelled state. The invention also refers to method for preparing the formulation, comprising the steps of... Agent:

20150037431 - Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities: Methods and kits for treating a cardiac arrhythmia using a platelet rich plasma (PRP) composition are provided. Any type of arrhythmia may be treated using the PRP composition. The PRP composition may comprise PRP developed using blood collected from a patient suffering the cardiac arrhythmia. The PRP composition may be... Agent:

20150037432 - Self-assembly of collagen fibers from dermis, fascia and tendon for tissue augmentation and coverage of wounds and burns: The present invention is a composition of a self-assembly of collagen fibers made from a plurality of sized pieces of a source material. The source material made from animal or human tissue selected from one of dermis, tendon, fascia or dura mater. The self-assembly occurring by induction of a magnetic... Agent: Vivex Biomedical Inc.

20150037433 - Method for preparing biological tissue: A method for preparing tissue for medical applications, in particular tissue for use for an artificial heart valve, wherein the method has the steps of decellularizing the tissue by means of a detergent and subsequently cross-linking the collagen fibers of the tissue by means of a suitable cross-linking agent. At... Agent:

20150037434 - Biomaterials derived from tissue extracellular matrix: Region-specific extracellular matrix (ECM) biomaterials are provided. Such materials include acellular scaffolds, sponges, solutions, and hydrogels suitable for stem cell culture.... Agent:

20150037436 - Acellular soft tissue-derived matrices and methods for preparing same: An acellular soft tissue-derived matrix includes a collagenous tissue that has been delipidated and decellularized. Adipose tissue is among the soft tissues suitable for manufacturing an acellular soft tissue-derived matrix. Exogenous tissuegenic cells and other biologically-active factors may be added to the acellular matrix. The acellular matrix may be provided... Agent: Musculoskeletal Transplant Foundation

20150037435 - Culture medium of adipose-derived stem cell, method for preparing the same, and composition including the same for promoting hair growth: Provided are a culture medium of an adipose-derived stem cell, a method for preparing the same, and a composition for promoting hair growth, in which the composition includes the culture medium. The adipose-derived stem cell (ADSC-T) according to the present invention exhibits long lifespan, improved cell proliferation rate, and extended... Agent:

20150037437 - Glioma treatment: A chemotherapy agent or a pharmaceutical composition including chemotherapy agent and artificial cerebrospinal fluid, wherein the chemotherapy agent at a concentration of between 0.01 mg/ml and 0.7 mg/ml for use in the treatment of brain cancer and a method of treating a glioma including administering a chemotherapy agent via convection... Agent: Renishaw PLC

20150037438 - Chewable gelled emulsions: An oral pharmaceutical composition in unit dose form, each unit dose comprising a lipophilic drug substance within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion.... Agent:

20150037439 - Phytogenic nutraceutical composition and methods of use thereof: A nutraceutical composition including as a functional ingredient an effective amount of a substance extracted from dry, fresh or ensilaged phytomass of genus Amaranthus L., in particular of Amaranthus cruentus L., is provided, and the methods of application thereof in poultry. The nutraceutical composition may be utilized as a veterinary... Agent:

20150037440 - Method for suppressing and relieving itching and inflammation: The present invention provides a method for suppressing and relieving itching and inflammation, by administering to a host in need of such treatment an effective amount of the pharmaceutical composition containing highly lipophilic polyalkoxyflavonoid. The pharmaceutical composition and functional food of the present invention for suppressing and relieving itching and... Agent: Kands R&d Corporation

20150037441 - Pharmaceutical composition for preventing and treating chronic obstructive pulmonary diseases, containing phyllostachys nigra munro var henosis stapf extract as active ingredient: The present invention relates to a method for treating chronic obstructive pulmonary disease (COPD) comprising the step of administering the extract of Phyllostachys nigra Munro var. henosis Stapf as an active ingredient. Particularly, the extract of Phyllostachys nigra Munro var. henosis Stapf of the present invention can reduce the numbers... Agent: University-industry Cooperation Group Of Kyung Hee University

20150037442 - Composition to enhance the bioavailability of curcumin: A composition having a curcuminoid and an essential oil of turmeric. A composition having a curcuminoid and an essential oil of turmeric, wherein the essential oil is present in an amount sufficient to cause an enhancement of bioavailability of curcumin when the composition is administered to a human as compared... Agent: Arjuna Natural Extracts, Ltd.

  
01/29/2015 > 178 patent applications in 104 patent subcategories.

20150030534 - Antibody cocktails for breast cancer radioimmunotherapy: The present invention provides compositions comprising a therapeutically effective combination of at least two of radionuclide-labeled anti-Epidermal Growth Factor Receptor (anti-EGFR), radionuclide-labeled anti-CD-44, and radionuclide-labeled anti-CD-73. or their respective antigen binding portions, and a pharmaceutically acceptable carrier, and method of use thereof for the treatment of breast cancer.... Agent:

20150030536 - Antigen associated with lung cancers and lymphomas: The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the treatment of lung cancer and lymphoma.... Agent: Philogen S.p.a.

20150030533 - Compositions and methods for the detection diagnosis and therapy of hematological malignancies: Disclosed are methods and compositions for the detection, diagnosis, prognosis, and therapy of hematological malignancies, and in particular, B cell leukemias, lymphomas and multiple myelomas. Disclosed are compositions, methods and kits for eliciting immune and T cell responses to specific malignancy-related antigenic polypeptides and antigenic polypeptide fragments thereof in an... Agent:

20150030535 - Meditopes and meditope-binding antibodies and uses thereof: Antibodies and meditopes that bind to the antibodies are provided, as well as complexes, compositions and combinations containing the meditopes and antibodies, and methods of producing, using, testing, and screening the same, including therapeutic and diagnostic methods and uses.... Agent:

20150030537 - Chlorotoxin polypeptides and conjugates and uses thereof: Reduced lysine chlorotoxin polypeptides that may be used to generate single species conjugates of chlorotoxin. Conjugates comprising such chlorotoxin polypeptides and pharmaceutical compositions thereof. Methods of using such compositions and/or conjugates.... Agent:

20150030538 - Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof: The present invention provides methods for treating, detecting and locating recurrence of cancer, radiation and chemo insensitive cancer or metastasis of cancer selected from the group consisting of Lung cancer, Adrenal cancer, Melanoma, Colon cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Liver cancer, Subcutaneous cancer, Squamous cell cancer, Intestinal cancer,... Agent: Cellectar, Inc.

20150030539 - Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors: This invention relates to novel compounds suitable for labelling or already labelled by 18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).... Agent: Piramal Imaging Sa

20150030540 - Imaging agents for detecting neurological dysfunction: Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled carbazoles and derivatives thereof and triazoles... Agent:

20150030541 - Nanoparticle peg modification with h-phosphonates: The present invention provides phosphonate conjugates and methods of preparing the phosphonate conjugates so as to allow, for example, improved methods and compounds for modifying the surface of a nanoparticle to increase in vivo circulation times and targeted delivery performance.... Agent:

20150030544 - Enzymatic nanosensor compositions and methods: Disclosed herein are compositions including a nanosensor that is sensitive to an analyte such that the nanosensor emits a fluorescent signal upon detecting the analyte, and a catalytic agent that catalyzes a reaction in which a target substrate is converted into one or more products, such that at least one... Agent:

20150030543 - Formulas for diagnosing and treating hormone-dependent cancers and cancers of the organs responsible for steroid hormone synthesis: The present invention relates to a formulation of a therapeutic or diagnostic agent in the form of a nano-emulsion, to its preparation method and to the use of this formulation for treating or diagnosing hormone-dependent cancers or cancers of organs synthesizing steroidal hormones.... Agent: Commissariat &#xe0 L'&#xe9 Nergie Atomique Et Aux &#xe9 Nergies Alternatives

20150030542 - Methods for medical imaging: The invention relates to methods of identifying, detecting, and locating a tissue(s), nodule(s) or mass(es) and its draining lymph nodes that is/are suspected to be abnormal, typically a neoplasm (i.e., cancer, malignancy, premalignancy) in an individual undergoing an invasive procedure (i.e., surgery or endoscopy) or a non-invasive procedure (ie. radiology).... Agent:

20150030545 - Molecular code systems: The present invention relates to a method for protecting and. recovering nucleic acids. This method may be applied in a verification method of products using molecular code systems or it may be applied in a storage method for nucleic acids. The invention further provides specific particles, their use in secure... Agent: Eth Zurich

20150030546 - Oral care product formulation: A two-part oral care system includes a first vessel containing an oxidative composition having a pH less than 7.5 and a second vessel containing a reductant composition having a pH greater than 7. The first and second vessels isolate the oxidative and reductant compositions from reacting with one another during... Agent:

20150030547 - Partial melt co-crystallization compositions: A co-crystallization composition containing erythritol and an active; a method of making the co-crystallization composition; and a method of using the co-crystallization composition are disclosed.... Agent:

20150030550 - Composition containing at least one c7 sugar for alopecia treatment, cosmetic treatment of hair and nails, and care of hair, eyelashes or nails: The present invention relates to a composition including at least one C7 sugar, or derivative from esterification of said sugar, and a pharmaceutically acceptable carrier for treating alopecia. The present invention also relates to a method for cosmetically treating hair and nails, said method being intended to stimulate the growth... Agent: Laboratoires Expanscience

20150030548 - External preparation for skin: The present invention relates to an external preparation for skin containing pollen extract of palm of the genus Elaeis guineensis in an amount between 0.05% and 1.00% by weight, based on the total weight of the external preparation, for whitening skin.... Agent: Sime Darby Malaysia Berhad

20150030549 - Topical compositions: Topical compositions are disclosed that are useful for delivering a therapeutic level of an NSAID to a target within a subject having a local inflammatory disorder. A composition of the present invention comprises a Drug and a solvent system, wherein the solvent system comprises at least two solvent alcohols and... Agent:

20150030551 - Benzopyran compounds as melanogenesis modifiers and uses thereof: wherein R3, R4, R5, R6, R7 and R8 are described herein. Also provided are plant extracts containing a compound of formula I, and the use of such a plant extract to modulate (e.g., inhibit) melanogenesis and pigmentation. The compound or plant extract may be prepared as pharmaceutical and cosmetic compositions,... Agent:

20150030552 - Cosmetic composition: A composition for topical application to human skin having an effective amount of cosmetically suitable components comprising at least one nut oil, at least one thickener and/or emulsifier component and water. The at least one nut oil includes a substantial proportion of macadamia nut oil, and the composition includes only... Agent: Climax Holdings Pty Limited

20150030553 - Use of isosorbide monoesters as thickeners: c

20150030554 - Shine-producing hair treatment agent: Agents for cosmetically treating keratin-containing fibers, in particular human hair, contain in a cosmetically acceptable carrier (i) at least one ester of formula (I), where R1 stands for a linear or branched (C2-C30) alkyl group, a linear or branched (C8-C30) alkenyl group, a (C2-C30) alkylpoly(oxyethylene) group, an optionally substituted aryl... Agent: Henkek Ag & Co. Kgaa

20150030557 - Benefit agent emulsions and consumer products containing such emulsions: Consumer product compositions providing enhanced hydrophobic benefit agent deposition. The benefit agent is provided as a benefit agent/deposition aid emulsion, where the benefit agent is physically adsorbed to the deposition aid before the emulsion is added to the balance of ingredients.... Agent:

20150030556 - Blocky cationic organopolysiloxane: Disclosed herein are inventive blocky cationic organopolysiloxanes and consumer product compositions comprising such organopolysiloxanes. Such compositions can deposit effectively onto target substrates to deliver consumer-desired benefits such as conditioning, anti-wrinkle, softness, and anti-static.... Agent:

20150030555 - Branched blocky cationic organopolysiloxane: Disclosed herein are inventive branched blocky cationic organopolysiloxanes and consumer product compositions comprising such organopolysiloxanes. Such compositions can deposit effectively onto target substrates to deliver consumer-desired benefits such as conditioning, anti-wrinkle, softness, and anti-static.... Agent:

20150030558 - Skincare compositions: The present disclosure relates to compositions. More particularly, the present disclosure relates to skincare composition. The present disclosure also relates to methods of forming extracts for inclusion in skincare compositions.... Agent:

20150030559 - Compositions and methods for treating and preventing skeletal muscle deficiencies: The present invention relates to compositions and methods for treating and preventing skeletal muscle deficiencies. In particular, the present invention provides compositions comprising poloxamers (e.g., poloxamer 188-P188) and methods of using the same for treating and preventing skeletal muscle deficiencies and injuries (e.g., dystrophin-deficient skeletal muscle; skeletal muscle having a... Agent:

20150030560 - Treatment of autoimmune conditions with copolymer 1 and related copolymers: The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one... Agent: Yeda Research And Development Co., Ltd.

20150030561 - Use of cxcr4 antagonists: Presently disclosed are methods and compositions for treating or preventing WHIM syndrome and certain other disorders or conditions with a certain CXCR4 antagonist.... Agent: University Of Washington Center For Commercialization

20150030562 - Methods of treating or preventing viral diseases by blocking interleukin-21: The invention provides a method of treating or preventing viral diseases in a mammal comprising administering to the mammal an interleukin (IL)-21 blocking agent in an amount effective to treat or prevent the viral disease in the mammal. Also provided is a method of reducing the activation or recruitment of... Agent: The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services

20150030563 - Compound for the treatment of enteroviruses: The present invention relates to the treatment, alleviation, prevention or reduction in the incidence of symptoms, diseases or conditions resulting from or associated with enteroviruses, more particularly the enteroviral infections they cause.... Agent:

20150030564 - Inhibitory agent for body cavity fluid accumulation: An inhibitory agent for body cavity fluid accumulation exerts a drug efficacy on body cavity fluid accumulation that is resistant to administration of diuretics, and is capable of exerting therapeutic effects even by systemic administration. The inhibitory agent for body cavity fluid accumulation includes, as an active ingredient, a covalent... Agent: Toray Industries, Inc.

20150030565 - Purification of flaviviruses: The present invention provides a method to prepare purified enveloped (e.g., flavivirus) viral particle preparations employing ion exchange chromatography and tangential flow filtration.... Agent: Sanofi Pasteur Biologics, LLC

20150030573 - Bacterial mediated thf alpha gene silencing: Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating an inflammatory disease or disorder. The bacterium... Agent: Beth Israel Deaconess Medical Center

20150030574 - Cells genetically modified to comprise pancreatic islet glucokinase and uses thereof: The present invention relates generally to a population of cells genetically modified to produce insulin in a glucose responsive manner and uses thereof. More particularly, the present invention relates to a population of cells genetically modified to produce insulin in response to physiologically relevant levels of glucose and uses thereof.... Agent: University Of Technology, Sydney

20150030576 - Methods and compositions for targeting agents into and across the blood-brain barrier: This invention relates to modified nucleic acid compositions encoding therapeutic polypeptides and methods of producing the therapeutic polypeptides in cells.... Agent:

20150030575 - Orally administered plastid expressed cholera toxin b subunit-exendin 4 as treatment for type 2 diabetes: Disclosed herein are compositions and methods for treating Type II diabetes. The compositions comprise plant expressed Exendin 4. Particularly exemplified are plant derived compositions that include a CTB-EX4 conjugate that is bioencapsulated in chloroplasts.... Agent:

20150030566 - Antimicrobial peptide compositions for plants: Compositions containing one or more tyrocidines, tryptocidines, phenycidines and/or gramicidin S, or derivatives and analogues thereof, are described for controlling antimicrobial growth on plants, plant material or plant growth media, and methods for controlling or preventing the growth of microbial pathogens, and in particular fungal pathogens, on plants, plant parts... Agent:

20150030577 - Control of phytopathogenic microorganisms with pseudomonas sp. and substances and compositions derived therefrom: Provided are compounds and compositions derived from Pseudomonas sp., particularly, Pseudomonas fluorescens or Pseudomonas protegens and more particularly strain having the identifying characteristics of Pseudomonas ATCC 55799 having antimicrobial properties and particularly, antibacterial properties.... Agent: Marrone Bio Innovations, Inc.

20150030567 - Cancer therapy with a parvovirus combined with an hdac inhibitor: Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a histone deacetylase inhibitor (HDACI) and the use of said composition for treatment of cancer, e.g., brain tumor, cervical carcinoma, or pancreatic carcinoma.... Agent:

20150030570 - Culture medium for preparing neural stem cells and use thereof: Provided are a culture medium for preparing neural stem cell and use thereof, the culture medium for preparing neural stem cell comprising: a basic culture medium suitable for the growth of stem cell, and a cell signal pathway inhibitor selected from at least one of GSK inhibitor, MEK inhibitor, TGF-β... Agent: Guangzhou Institutes Of Biomedicine And Health Chinese Academy Of Sciences

20150030572 - Identification of molecular pathways and methods of use thereof for treating retinal neurodegeneration and other neurodegenerative disorders: Drug targets, pathways, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed.... Agent: The Johns Hopkins University

20150030569 - Methods for inducing immune tolerance to organ transplants: The present invention is directed to methods of treating an organ or a tissue prior to transplantation thereof into a recipient, comprising ablating the cells composing the blood vessels of said organ or tissue, preferably the cells lining the lumen surface of the blood vessels, thereby obtaining a treated viable... Agent:

20150030571 - Preparation and method for producing a preparation comprising mesenchymal stem cells: Preparation and method for producing a preparation or a tissue derivative that include mesenchymal stem cells, to be used in cellular therapy, for cosmetic treatments, for replacing a tissue or an organ, or inducing or accelerating tissue repair or regeneration. The method includes the steps of extracting tissue containing mesenchymal... Agent: Lipogems International S.p.a.

20150030568 - Use of stem cells to generate inner ear cells: This invention relates generally to methods and compositions for inducing stem cell or progenitor cell differentiation, and more particularly to methods and compositions for inducing differentiation of stem cells and/or progenitor cells into cells that function within the inner ear.... Agent: Massachusetts Eye And Ear Infirmary

20150030578 - Method for producing activated autologous platelet rich and platelet poor plasma and methods of use: A method and kit to produce activated autologous platelet rich and platelet poor plasma (AAPRPP) and methods of use to treat pain. The method to produce AAPRPP generally comprising (1) obtaining whole blood from patient; (2) centrifuging whole blood in a collection tube; (3) extracting platelet rich and platelet poor... Agent:

20150030579 - Hydroxytyrosol combinations for enhancing mitochondrial function and energy production: Hydroxytyrosol or olive juice containing hydroxytyrosol in combination with at least one of the compounds selected from the group consisting of: creatine, coenzyme Q10, resveratrol, caffeine, carnitine, B vitamins (B1, B2, B3, B5, B6, and/or B12) and ginseng (preferably: root) extract. can be used to maintain or increase mitochondrial biogenesis... Agent: DsmIPAssets B.v.

20150030580 - Pegylated fibrinogen precursor molecule: The present invention relates to biodegradable scaffolds composed of a naturally-occurring protein backbone cross-linked by a synthetic polymer. Specifically, the present invention provides PEGylated-fibrinogen scaffold and methods of generating and using same for treating disorders requiring tissue regeneration.... Agent:

20150030581 - Lpl variant therapeutics: The invention provides for the use of a therapeutic derived from a truncated lipoprotein lipase protein (LPL S447X), including nucleic acids encoding such proteins, for the treatment of conditions including LPL responsive conditions, such as cardiovascular disease, hypertension, LPL deficiency, high triglyceride levels, low HDL-cholesterol levels or atherosclerosis.... Agent:

20150030582 - Lysosomal storage disease enzyme: The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of... Agent: Synageva Biopharma Corp.

20150030583 - Methods of treating serosal cancer: The discovery of clonally pure populations of serosal cancer stem cells (CSCs) as well as methods of producing CSCs, culturing the CSCs and using them in screening assays, has lead to the development of methods of treating serosal and ovarian cancers by targeting removal or inhibition of the glycocalyx coat... Agent: Sloan Kettering Institute For Cancer Research

20150030584 - Transport protein which is used to introduce chemical compounds into nerve cells: The invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum. The protein binds specifically to nerve cells with a higher affinity as the native neurotoxin. The invention also relates to a method for the production of transport... Agent: Syntaxin Limited

20150030589 - Abeta antibody formulation: The present invention relates to a pharmaceutical formulation comprising about 50 mg/ml-200 mg/ml of an Abeta antibody, about 0.01%-0.1% poloxamer, about 5 mM-50 mM of a buffer, about 100 mM-300 mM of a stabilizer at a pH of about 4.5-7.0.... Agent:

20150030588 - Combination of kinase inhibitors and uses thereof: The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or a receptor tyrosine kinase (RTK) in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or an RTK in a subject. In... Agent:

20150030586 - Compositions and methods for the therapy and diagnosis of cancer: Compositions and methods for the therapy and diagnosis of cancer are disclosed. For example, illustrative compositions comprise one or more cancer-associated antibodies, polypeptides, polynucleotides, antigen presenting cells, and the like. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly cancer.... Agent:

20150030585 - Compositions including triciribine and one or more platinum compounds and methods of use thereof: This application encompasses combination therapies including triciribine and related compounds and one or more platinum compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.... Agent: University Of South Florida

20150030591 - High concentration antibody and protein formulations: Provided are salt-free antibody and other protein formulations that are substantially isosmotic and of low viscosity. Also provided are methods for the treatment of diseases using the disclosed formulations.... Agent:

20150030587 - Human papilloma virus as predictor of cancer prognosis: Methods of treating a head and neck cancer are disclosed.... Agent: Foundation Medicine, Inc.

20150030592 - Optimized fc variants: The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.... Agent: Xencor, Inc.

20150030590 - Treatment of severe multiple sclerosis: Methods of treating multiple sclerosis are disclosed.... Agent: Biogen Idec Ma Inc.

20150030597 - Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer: The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of a KDR-1121 or DC101 antibody, an extracellular hinge domain, a T cell receptor transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen... Agent:

20150030594 - Bioconjugates of synthetic apelin polypeptides: or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein and a half-life extending moiety wherein the peptide and the half-life extending moiety are covalently linked or fuse, optionally via a linker. The... Agent: Novartis Ag

20150030596 - Bispecific chimeric proteins with darpins: A bispecific chimeric protein including a designed ankyrin repeat protein (DARPin), and an IgG antibody, an scFv-Fc antibody fragment, or a combination thereof, linked to the DARPin; a method for treating or preventing cancer using the same; and related methods and compositions.... Agent:

20150030593 - Compositions of penetration-enhanced targeting proteins and methods of use: The disclosure relates to penetration-enhanced targeted proteins and their uses for therapeutics delivery.... Agent: Permeon Biologics, Inc.

20150030595 - Myostatin inhibitor comprising extracellular water-soluble domains of dlk1 as active ingredient: The present invention relates to a myostatin inhibitor comprising extracellular water-soluble domains of delta-like 1 homolog (DLK1) as active ingredients. More particularly, the present invention relates to a composition for inhibiting myostatin activity, comprising, as active ingredients, extracellular water-soluble domains of DLK1 or a deletion mutant of extracellular water-soluble domains... Agent:

20150030599 - Anti-egfr antibody and anti-c-met/anti-egfr bispecific antibodies comprising the same: An anti-EGFR scFV fragment, an anti-c-Met/anti-EGFR bispecific antibody including the same, and a method of preventing and/or treating a cancer using the same are provided.... Agent:

20150030598 - Tri- or tetraspecific antibodies: The present invention relates to tri- or tetraspecific antibodies, their manufacture and use.... Agent:

20150030606 - Actriib binding agents and uses thereof: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.... Agent:

20150030603 - Anti-ang2 antibody: An anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes with a Tie2 receptor and Ang2, and related methods and compositions.... Agent:

20150030600 - Antibodies for botulinum neurotoxins: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are... Agent: The Regents Of The University Of California

20150030602 - Antibodies for the treatment and diagnosis of affective and anxiety disorders: A novel monoclonal antibody and like antigen-binding molecules against transmembrane protein with EGF-like and two follistatin-like domains 2 (TMEFE2) are provided with unique immunological and biological properties useful in the therapy of affective disorders such as depression and bipolar disorders as well as anxiety disorders. In addition, pharmaceutical compositions and... Agent: Phenoquest Ag

20150030601 - E1 enzyme mutants and uses thereof: The invention provides isolated nucleic acids molecules, designated UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid molecules, which encode novel E1 enzyme variant proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing UBA3, UAE, or UBA6, or other E1 enzyme variant nucleic acid... Agent: Millennium Pharmaceuticals, Inc.

20150030607 - Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection: Disclosed herein are neutralizing antibodies with cross-neutralizing activity and cross-protective effects against divergent stains of influenza virus, which are specific for an epitope having at least 90% homology to amino acids +72-115 of the HA1 domain of H5N1 influenza virus hemagglutinin.... Agent:

20150030604 - Method of blocking vascular leakage using an anti-ang2 antibody: A method for the prevention and/or treatment of a disease accompanied by vascular leakage and/or vascular inflammation comprising administering an anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and forms a complex with a Tie2 receptor and Ang2.... Agent:

20150030608 - Method of treating crohn's disease by administering an anti-il-12 antibody: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids... Agent:

20150030605 - Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof: The invention encompasses polypeptides, polynucleotides, and antibodies, for Artemin and related ligands, including Persephin (PSPN). The invention also encompasses expression vectors and host cells for producing these polypeptides, polynucleotides, or antibodies. The invention further encompasses diagnostics and therapeutics, especially for cancer, and particularly breast cancer, colon cancer, prostate cancer, endometrial... Agent:

20150030609 - Diagnosis and treatment of traumatic brain injury: The subject invention identifies CC chemokine ligand 20 (CCL20) as a novel biomarker for diagnosis of traumatic brain injury and/or neurodegeneration in the brain. The subject invention also provides treatment methods for traumatic brain injury and/or neurodegeneration in the brain by modulating systemic and/or brain-specific CCL20-CCR6 signaling. Also provided are... Agent: University Of South Florida

20150030612 - Immunization against clostridium difficile disease: The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of... Agent:

20150030610 - Increasing taxane sensitivity in cancer cells: Disclosed herein are combinatorial therapies for treating or preventing reoccurrence of cancer. The therapies involve inhibition of LIMK1 in conjunction with taxane therapy. Specifically exemplified herein is co-administration of a LIMK1 RNA interfering molecule along with administration of a taxane.... Agent: University Of Central Florida Research Foundation, Inc.

20150030611 - Monitoring and modulating hgf/hgfr activity: Provided are methods and compositions for the modulation of hepatocyte growth factor activity to regulate lymphatic vessel development and function. Methods and composition for the monitoring and treatment of skin disorders, lymphedema, and metastatic cancers are disclosed. Also described are methods of identifying inhibitors of hepatocyte growth factor dependent lymphangiogenesis.... Agent: The General Hospital Corporation

20150030613 - Treatment of mucositis with immunoglobulin: The invention relates to compositions comprising immunoglobulin for use in the treatment of mucositis by topical application. In particular, the invention relates to compositions comprising J chain-containing IgA and secretory component for the treatment of mucositis.... Agent:

20150030614 - Antibodies to the pcrv antigen of pseudomonas aeruginosa: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.... Agent:

20150030615 - Biomarkers for cancer stem cells and related methods of use: Novel methods of classifying subjects as candidates for treatment with a cancer associated mesenchymal cell, tumor initiating cancer cell, or cancer stem cell inhibitor treatment and subsequent administration of the cancer associated mesenchymal cell, tumor initiating cancer cell, or cancer stem cell inhibitor are disclosed within.... Agent:

20150030616 - Novel benzodiazepine derivatives: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine... Agent:

20150030617 - Low density lipoprotein - related protein 6 (lrp6) - half life extender constructs: The present invention relates to LRP6 constructs that bind to LRP6 receptor. The LRP6 constructs comprise at least one LRP6 binding moiety and a half-life extender molecule such that the LRP6 construct inhibit the Wnt signaling pathway without potentiation of the Wnt signal. The LRP6 constructs also have an increased... Agent:

20150030618 - Novel binder-drug conjugates (adcs) and use thereof: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for... Agent: Seattle Genetics, Inc.

20150030619 - Activation and expansion of t cell subsets using biocompatible solid substrates with tunable rigidity: The present invention provides compositions and methods for activation and expansion of T cells using a biocompatible solid substrate with tunable rigidity. Rigidity of a substrate is an important parameter that can be used to control the overall expansion and differentiation of T cells.... Agent: The Trustees Of Columbia University In The City Of New York

20150030621 - Baculovirus-based vaccines: The present invention relates to a recombinant baculovirus comprising: (a) a nucleotide sequence encoding a foreign virus envelope protein; (b) a first promoter operatively linked to the envelope-encoding nucleotide sequence; (c) a nucleotide sequence encoding an antigen protein; and (d) a second promoter operatively linked to the antigen-encoding nucleotide sequence;... Agent:

20150030620 - Packaging of immunostimulatory substances into virus-like particles: method of preparation and use: The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against... Agent: Cytos Biotechnology Ag

20150030622 - Conformationally stabilized rsv pre-fusion f proteins: In some embodiments, the present invention provides respiratory syncytial virus (RSV) F proteins, polypeptides and protein complexes that comprise one or more cross-links to stabilize the protein, polypeptide or protein complex in its pre-fusion conformation. In some embodiments the present invention provides RSV F proteins, polypeptides and protein complexes comprising... Agent:

20150030623 - Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene: The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.... Agent: Universite Paris-sud

20150030624 - Campylobacter immunogenic compositions and uses thereof: The present invention provides immunogenic compositions against Campylobacter and methods for using the immunogenic composition to generate an immune response against Campylobacter and/or reduce intestinal colonization by Campylobacter.... Agent:

20150030625 - Gas57 mutant antigens and gas57 antibodies: The invention provides mutants of GAS57 (Spy0416) which are unable to cleave IL-8 and similar substrates but which still maintain the ability to induce protection against S. pyogenes. The invention also provides antibodies which specifically bind to GAS57 and which inhibit its ability to cleave IL-8 and similar substrates. The... Agent:

20150030626 - Immunomodulatory conjugates: The present invention provides an immunomodulatory compound comprising a carbohydrate polymer comprising mannose, wherein the carbohydrate polymer is conjugated to at least one immune modulator. The present invention also provides for the use of this compound in immunomodulatory compositions for vaccination and gene therapy methods, together with processes for its... Agent: Ascend Biopharamaceuticals Ltd

20150030627 - Trans-complementing, replication deficient lentiviral vectors and methods for making and using them: The present invention relates to multiple novel approaches for the generation of an immune response in an animal, such as a human, using lentivirus-based vector technology. The invention provides for the ability to mimic the efficacy of a live attenuated (LA) vaccine, without exposing the patient to the risk of... Agent: Virxsys.con390

20150030628 - Computationally optimized broadly reactive antigens for influenza: The development of a computationally optimized influenza HA protein that elicits broadly reactive immune response to all H5N1 influenza virus isolates is described. The optimized HA protein was developed through a series of HA protein alignments, and subsequent generation of consensus sequences, for clade 2 H5N1 influenza virus isolates. The... Agent: University Of Pittsburgh - Of The Commonwealth System Of Higher Education

20150030629 - Methods and compositions for stabilizing dried biological materials: The present invention relates to methods for producing dried formulations of biopharmaceutical agents that aim to minimize the loss of activity of the agents upon drying and to provide dried formulations with an extended shelf life. The method comprises the step of drying an aqueous solution comprising, in addition to... Agent: En Sport

20150030630 - Adjuvanted formulations of rabies virus immunogens: The efficacy of rabies vaccines can be enhanced by adjuvanting rabies virus immunogens with a mixture of a TLR agonist (preferably a TLR7 agonist) and an insoluble metal salt (preferably an aluminium salt). The TLR agonist is typically adsorbed to the metal salt. The rabies virus immunogen can also be... Agent: Novartis Ag

20150030631 - Compositions and methods for vaccinating against hsv-2: This invention relates to therapeutic compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The methods are particularly effective for protecting mammals from herpes simplex virus.... Agent: The University Of Washington

20150030632 - Fusion protein for enhancing immunogenicity of bacterial antigen/immunogen: Establishment of an effective and uniform vaccine development strategy is key to conquering current and emerging infectious diseases. Despite successes against an array of bacterial agents, current approaches to vaccine development are as diverse as the microbes they target and require adjuvants that often have limited efficacy and/or toxic side... Agent: Albany Medical College

20150030635 - Activated immunostimulatory cell composition and uses thereof: Methods of making activated immunostimulatory cell compositions, activated immunostimulatory cell compositions, and methods of using those compositions to stimulate therapeutic immune responses to tumors are described.... Agent:

20150030633 - Application of mrna for use as a therapeutic against tumour diseases: The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The... Agent: Curevac Gmbh

20150030636 - Identification and enrichment of cell subpopulations: Markers useful for the identification, characterization and, optionally, the enrichment or isolation of tumorigenic cells or cell subpopulations are disclosed.... Agent: Stem Centrx, Inc.

20150030634 - Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine: The purpose of the present invention is to provide a means for proliferating a monocyte with high efficiency and in a simple manner. The present invention provides a proliferating agent for a monocyte, which consists of at least one component selected from Flt-3L, IL-3 and IFN-γ and can be used... Agent: Hakushikouseikai Foundation

20150030637 - Reduction of non-starch polysaccharides and alpha-galactosides in soy flour by means of solid-state fermentation using cellulolytic bacteria isolated from different environments: The invention relates to a method for fermenting soy flour in the solid state in order to reduce non-starch polysaccharides and alpha-galactosides, said method comprising the following steps: a) preparation of the fermentation substrate; b) inoculation of the substrate with selected celluloytic bacterial strains; c) incubation; and, optionally, d) drying... Agent: Universidad De Chile

20150030638 - Ingenol derivatives in the reactivation of latent hiv: The present invention broadly relates to the use of certain ingenol derivatives as HIV reactivators of latent HIV virus in viral reservoirs. In another aspect, the present invention relates to an association comprising such ingenol derivatives and antiretroviral agents substantially active against actively replicating virus.... Agent: Amaz&#xd4 Nia Fitomedicamentos Ltda.

20150030639 - Devices and methods for weight control and weight loss: The present invention provides, compositions, devices; and methods for affecting, among other things, weight loss and/or weight control, by sequestering nutrients or other compounds such as toxins from absorption in the digestive tract. The compositions, devices, and methods employ one or more members made of a compressible, absorbent matrix material.... Agent: Primigenia, LLC

20150030641 - Glucose-responsive microgels for closed loop insulin delivery: Injectable insulin loaded microgels that are capable of modifying the amount of insulin released based on the patient's tissue glucose levels, methods for making and using these compositions have been developed. The microgels contain insulin, glucose oxidase entrapped in or bound to the microgels, and an agent that reduces hydrogen... Agent:

20150030640 - Method for preparing an adsorbed drone brood and the composition thereof: The invention relates to the pharmaceutical and food industries, to medicine, and in particular, to biologically active food supplements, and describes the process of obtaining an adsorbed drone brood, and the composition thereof that ensures the preservation and stabilization of all biological properties of the drone brood over a long... Agent:

20150030642 - Polymer micro-needle array chip, preparation process and use thereof: The invention discloses a polymer micro-needle array chip, comprising a substrate and a micro-needle array standing thereon; the material for preparing the micro-needle array is a polyacrylamides polymer, with the molecular weight of 1.0×104-2.0×105, the Vickers hardness of 150-600 HV, and the impact strength of 5-30 J/m. The polymer micro-needle... Agent: Technical Institute Of Physics And Chemistry Of The Chinese Academy Of Sciences

20150030643 - Amino silicone nanoemulsion: The present invention relates to amino silicone nanoemulsions. More specifically, the present invention relates to amino silicone nanoemulsions that may be used to protect surfaces from being soiled or wetted.... Agent:

20150030644 - Amino silicone nanoemulsion: The present invention relates to amino silicone nanoemulsions. More specifically, the present invention relates to amino silicone nanoemulsions that may be used to protect surfaces from being soiled or wetted.... Agent:

20150030647 - Cosmetic composition: e

20150030649 - Cosmetic composition:

20150030648 - Dispersion intended for encapsulating an active product and associated use: A dispersion including a plurality of bodies dispersed in a continuous phase. Each dispersed body including an internal drop formed with an internal phase miscible with the continuous phase, the internal drop (16) receiving an active product. Each dispersed body including, around the internal drop, a membrane formed with an... Agent:

20150030650 - Liquid suspensions and powders of cerium oxide particles and preparation and polishing applications thereof: The invention relates to a suspension of cerium oxide particles, of which the particles (secondary particles) have an average size of at most 200 nm, these secondary particles consisting of primary particles whose average size measured by TEM is of at most 150 nm with a standard deviation of at... Agent:

20150030646 - Oral delivery products including three-dimensional objects: An edible product and method for making an edible product including a core composition having at least one outer surface and at least one edible, three dimensional object secured to the at least one outer surface, where the object includes a binder material and a deliverable component selected from the... Agent:

20150030645 - Solid cosmetic composition with magnetic effects: The present invention relates to a solid composition that is especially in the form of a product cast as a stick or in acupel, the said composition having an outer surface, and containing one or more magnetic bodies (1) of non-zero magnetic susceptibility, the said solid composition being characterized in... Agent:

20150030651 - Green biocidal application method for the perfect silver bullet exterminators: These formulations are comprised of ultra-fine extremely minute mini-nano-sized (nearly atom-sized low-voltage produced silver particles from 0.04 to 0.99 mnm mini-nanometers in diameter) that are clear color-less colloidal silver particles and ions in ultra-pure distilled water resulting in stable suspended preparations. The formulations can be used as medical devices suitable... Agent:

20150030652 - Block copolymers of acrylates and methacrylates with fluoroalkenes: A block copolymer comprising a fluorinated block and a non-fluorinated block and method of making the block copolymer are provided. Also provided herein are a coating on an implantable device comprising the block copolymer and method of using the implantable device.... Agent:

20150030656 - Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis: A composition comprising a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analogue is attached to and can be released from the osteoconductive material and... Agent:

20150030654 - Pdlla stent coating: An amorphous PDLLA stent coating for drug delivery is disclosed.... Agent: Advanced Cardiovascular Systems, Inc.

20150030655 - Plga scaffold: Disclosed is a PLGA (poly(D,L-lactide-co-glycolide)) cell scaffold. The cell scaffold is based on a PLGA scaffold, which is an FDA-approved material with no cytotoxicity, and overcomes the problem with conventional PLGA scaffolds of poor cell adhesion.... Agent: Daegu Gyeongbuk Institute Of Science And Technology

20150030653 - Vanadium compounds as therapeutic adjuncts for cartilage injury and repair: A method for repairing an injury of cartilage in a patient by local administration of an organovanadium agent or use of an implantable device for delivery of an organovanadium agent. Implantable devices containing an organovanadium agent and methods of making these implantable devices are also disclosed.... Agent: Rutgers, The State University Of New Jersey

20150030657 - Smooth muscle cell constructs: The present invention relates to the regeneration, reconstruction, augmentation or replacement of luminal organs or tissue structures in a subject in need using scaffolds seeded with autologous or non-autologous cell populations that are or are not derived from the corresponding organ or tissue structure that is the subject of the... Agent: Tengion, Inc.

20150030660 - Bone regeneration using biodegradable polymeric nanocomposite materials and applications of the same: A structure of, and a method of producing, a biocompatible structure for bone and tissue regeneration are disclosed. The method includes dissolving a polyurethane polymer in methanol, adding hydroxyapatite (HAP) nanoparticles to form a uniformly distributed mixture, applying the mixture to a polytetrafluoroethylene (PTFE) surface to form a polymer film,... Agent:

20150030658 - Generation of photoreceptors from human retinal progenitor cells using polycaprolactone substrates: The present invention relates to biocompatible compositions for transplantation into a sub-retinal space of the human eye. The compositions include a biodegradable polyester film, preferably a polycaprolactone (PCL) film, and a layer of human retinal progenitor cells. The compositions of the invention can be used as scaffolds for the treatment... Agent:

20150030659 - Methods and compositions for the treatment of open and closed wound spinal cord injuries: Devices and methods for the treatment of open and closed wound spinal cord injuries are disclosed. For example, described herein are devices and methods for mitigating secondary injury to, and promoting recovery of, spinal cord primary injuries. More particularly, certain embodiments of the present invention are directed to polymeric mini-tubes... Agent:

20150030662 - Generation of brown adipose tissue (bat) from mesenchymal cells: Methods of generating functional human brown adipocytes, comprising exposing human stem cells, progenitor cells, or white adipocytes to culture with an differentiation cocktail that comprises one or more browning agents (e.g., one or more macromolecular crowders), and optionally one or more adipogenic agents, are described, as are populations of human... Agent: Auckland Uniservices Ltd

20150030661 - Multilayer films and uses thereof: The invention provides, inter alia, multilayer films of alternating layers of a glycosylated polymer (e.g. a mucin) and a lectin, as well as methods of making and using these films. The films can be adapted for, inter alia, delivery of a biologically active agent providing a non-toxic substrate to support... Agent:

20150030663 - New wound dressing compositions: A wound dressing composition comprising a non-viable cell lysate or releasate derived from a hepatocyte cell or an inflammatory cell such as a macrophage. Also provided are wound dressings comprising such compositions, methods of making such compositions, and the use of such compositions for the treatment of wounds.... Agent:

20150030664 - Blood coagulation inducing polymer hydrogel: The present application is drawn to a synthetic, polymer hydrogel-based material, which is able to actively induce the body's natural hemostatic coagulation process in blood or acellular plasma. The present invention provides the development of a primary amine containing polymer hydrogel capable of inducing blood coagulation and delivering therapeutics for... Agent: University Of Maryland At College Park

20150030665 - Composition and method for treating connective tissue damage: The present invention provides a composition, and a method of use thereof, for treating connective tissue damage in man and in animals, which comprises a therapeutically effective amount of chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan (hyaluronic acid). Particularly, the present invention provides a composition, and a method of use thereof,... Agent:

20150030666 - Adhesive skin patch: The present invention provides an adhesive skin patch containing a support and an adhesive layer containing a drug which is formed on the support, wherein the adhesive layer comprises a thermoplastic elastomer, a liquid component in an amount exceeding 300 parts by weight per 100 parts by weight of the... Agent:

20150030670 - Aminoacid lipids: The present invention is directed to a new class of lipids, more specifically ether-lipids having a polar headgroup, as well as vesicles comprising these lipids, methods of their preparation as well as their uses in medical applications, wherein the ether-lipids are represented by general formula I... Agent: Merck Patent Gmbh

20150030667 - Compositions and methods for treating underactive bladder: Methods and compositions for treating underactive bladder and/or symptoms thereof are disclosed, wherein the composition including an effective amount of a therapeutic agent and a pharmaceutically acceptable lipid vehicle is locally administered to the bladder, thereby treating the underactive bladder and/or symptoms thereof.... Agent: Lipella Pharmaceuticals, Inc.

20150030668 - Liposomally encapsulated reduced glutathione for management of cancer, including with other pharmaceutical compositions: This invention proposes an agent to block the “fuel supply” that energizes cancer cell growth by protecting surrounding cells to the cancer, particularly stromal fibroblast cells. The invention disables the products of surrounding cells useable for energy conversion by the cancer cell thereby crippling the cell and disabling its growth... Agent:

20150030672 - Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt: A liposome comprising bilayer and inner water phase is disclosed. Said inner water phase may contain sulfobutyl ether cyclodextrin and an active compound.... Agent:

20150030671 - Methods and formulations for enhancing the absorption and decreasing the absorption variability of orally administered drugs, vitamins and nutrients: A method of preparing and composition of bioavailable hydrophobic, poorly water soluble drugs. It uses for example, lecithin, sterol, a calcium salt, and solvent; mixing to form liposomes and then the solvent driven off; the ratios used and physical form differ from others, and maximize performance.... Agent:

20150030669 - Targeting aminoacid lipids: The present invention is directed to carrier systems comprising ether-lipids conjugated to one or more bioactive ligands and exposed on the surface of the carrier system for use in targeted delivery and/or antigen display systems. Optionally one or more further bioactive agents may be encapsulated or embedded within or attached... Agent: Merck Patent Gmbh

20150030673 - Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-indazol-5-yloxy)benzyl)urea hydrochloride: Provided herein is a hydrogen chloride salt of 1-(3-/t?r/-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea, crystalline forms of 1-(3-½̂butyl-1̂-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea hydrochloride, processes for the preparation of said crystalline forms, pharmaceutical compositions containing a crystalline form of 1-(3-r<i/-r-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea hydrochloride Form B, processes for the preparation of said compositions, pharmaceutical compositions prepared by said methods, and the use of... Agent: Array Biopharma Inc.

20150030674 - Composition for polyunsaturated fatty acids encapsulation and process of preparation: The application relates to an encapsulated composition comprising from about 40% (w/w) to about 90% (w/w) of the encapsulating composition comprising from about 14% (w/w) to about 90% (w/w) whey protein isolate with a special ionic profile, from about 5% (w/w) to about 80% (w/w) of one or more low... Agent: Corn Products Development, Inc.

20150030675 - Controlled release dosage forms: The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.... Agent: Valeant International Bermuda

20150030676 - Stablized modified release folic acid derivative composition, its therapeutic use and methods of manufacture: This invention relates to an oral stabilized modified release pharmaceutical dosage form containing L-methylfolate calcium, which is primarily absorbed from proximal small intestine via a saturable human proton-coupled folate transporter (h-PCFT) mediated transport intended as monotherapy for the treatment of patients with MDDs and/or diagnosed with dysthymia, schizophrenia, or degenerative... Agent:

20150030677 - Tamper resistant immediate release formulations: Disclosed is an immediate release solid oral dosage form comprising (i) an active agent; and (ii) a material that is sensitive to acidic pH;... Agent: Rhodes Pharmaeuticals L.p.

20150030678 - Methods and compositions for treating wounds and reducing the risk of incisional hernias: Provided are methods and compositions for treating a wound in a subject. The methods include applying a pharmaceutical composition that includes a first precursor material agent including fibrinogen, a second precursor material agent including thrombin, and silver particles to an abdominal incision site in an amount effective to treat the... Agent: The Regents Of The University Of California

20150030680 - Oral pharmaceutical compositions of dabigatran etexilate: Compositions comprising a mixture of at least two types of particles wherein a) the first type of particles comprise dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates or hydrates thereof; and b) the second type of particles comprise at... Agent:

20150030679 - Stable, durable granules with active agents: A stable, durable granule for feed compositions has a core, at least one active agent; and at least one coating. The active agent of the granule retains at least 50% activity, at least 60% activity, at least 70% activity, at least 80% activity after conditions selected from one or more... Agent: Danisco US Inc.

20150030682 - Antigenic compositions and methods: Multilayer films comprised of polypeptide epitopes and a toll-like receptor ligand. The multilayer films are capable of eliciting an immune response in a host upon administration to the host. The multilayer films can include at least one designed peptide that includes one or more polypeptide epitopes from a virus, bacteria,... Agent:

20150030681 - Method of making a hydrogel: The present invention relates to a novel protocol for making a hydrogel, which shows increased stability compared to hydrogels of the art, and can be reliably reproduced. The hydrogels produced by the methods of the present invention are preferably three dimensional, and particularly suitable for the culture of stem cells.... Agent: The University Of Manchester

20150030683 - Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer's conditions: In certain embodiments the methods of preventing or delaying the onset of a pre-Alzheimer's condition and/or cognitive dysfunction, and/or ameliorating one or more symptoms of a pre-Alzheimer's cognitive dysfunction, and/or preventing or delaying the progression of a pre-Alzheimer's condition or cognitive dysfunction to Alzheimer's disease, and/or of promoting the processing... Agent:

20150030684 - Irrigation resistant compositions for regeneration of hard tissues and methods and kits of using the same: An irrigation resistant bone repair composition including a biocompatible or bioactive bone repair material and a mixture of non-random poly(oxyalkylene) block copolymers is described. Also, methods for treating a bone having a bone gap or a bone defect with the composition including a biocompatible or bioactive bone repair material and... Agent:

20150030685 - Sugar-free oral transmucosal fentanyl citrate lozenge dosage forms: A sugar-free, pharmaceutical composition comprising an oral transmucosal solid dosage form which includes an adherent carrier preblend mixture of a highly potent pharmaceutical agent, and dextrates, hydrated the composition further including a pharmaceutically acceptable sugar-free excipient.... Agent:

20150030686 - Self-assembled toroidal-spiral particles and manufacture and uses thereof: Toroidal-spiral shaped particles, their method of manufacture, and uses thereof are disclosed. The toroidal-spiral particles can contain at least one active agent, such as a drug, and provide a controlled, sustained release of the active agent.... Agent:

20150030687 - Use of fermented milk product for skin treatment: The use of a fermented milk product comprising non-hydrolysed whey proteins which is substantially free of casein proteins for the purpose of improving skin firmness, by structuring collagen without promoting collagen synthesis, when topically applied to skin is provided.... Agent:

20150030688 - Honey and growth factor eluting scaffold for wound healing and tissue engineering: Tissue engineering structures with biologically favorable structural and chemical properties are disclosed. More particularly, the present disclosure is directed to tissue engineered scaffolds having a fiber support and honey. The tissue engineered scaffolds having a fiber support and honey can further include at least one biomolecule. The tissue engineered scaffolds... Agent:

20150030689 - Phytoseiid predatory mite releasing system and method for production: The present invention in general relates to the field of biological crop protection by use of phytoseiid predatory mites. More particularly the present invention relates to a system for releasing a phytoseiid predatory mite in a crop and novel uses of host mites in such phytoseiid predatory mite releasing system.... Agent: Koppert B.v.

20150030690 - Prebiotic mixture: The present invention refers to a prebiotic mixture comprising at least one plant polysaccharide fibre and at least one of Propolis and/or Olea europaea and/or Aloe vera extracts, optionally comprising also Thymus vulgaris and/or Agrimonia eupatoria extracts. Moreover, the present invention also relates to said mixture for use in the... Agent:

20150030691 - Analgesics based on snake venoms: A homeopathic pain topical analgesic composition based on snake venom is disclosed. The study product also contained of Arnica montana, a homeopathic remedy most frequently used for fractures, bruises, and muscle strains due to its analgesic and anti-inflammatory effects. The composition also contained a penetrant component to enhance penetration of... Agent:

20150030692 - Treatment for chronic pain syndromes: A method is described to treat chronic pain syndromes by treating extracorporeally a patient's cerebrospinal fluid (CSF). A patient's CSF is treated extracorporeally using a moiety that targets an antigen in the CSF. This moiety facilitates removal of the CSF antigen. The cleansed CSF is then returned to the patient.... Agent:

20150030693 - Anti-tumor aqueous solution, anti-cancer agent, and methods for producing said aqueous solution and said anti-cancer agent: An object of the present invention is to provide an antitumor aqueous solution and an anticancer agent, both of which can kill cancer cells while having virtually no effects on normal cells, and to provide methods for producing the antitumor aqueous solution and the anticancer agent. The method of the... Agent: Nu Eco Engineeering Co., Ltd.

20150030694 - Formulations and methods for treating oral inflammation, injury, or pain: The present invention generally relates to formulations and methods for treating oral inflammation, oral injury and/or oral pain by applying hydrogel, viscous liquid, or other formulation to the oral cavity. Wet formulations comprise a hydrophilic polymer selected from the group consisting of pyrrolidones, hyaluronic acid and salts thereof, alginic acid... Agent:

20150030695 - Capsule and powder formulations containing lanthanum compounds: The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical... Agent:

20150030696 - Ceramic glaze having antimicrobial property: An antimicrobial ceramic glazing composition contains one or more antimicrobial agents disposed therein. Methods for making and using the glazing composition are disclosed, as well as substrates having a fired antimicrobial glaze thereon. The antimicrobial agents comprise metallic oxides, with a subset of the disclosed combinations exhibiting synergistic effect in... Agent:

20150030697 - Treatments for gastrointestinal disorders: The present invention provides pharmaceutical compositions and methods of treating lower gastrointestinal disorders, including irritable bowel syndrome and constipation.... Agent: Ironwood Pharmaceuticals, Inc.

20150030698 - Powdered drink mix for recovery: An oral product that includes an amino acid nitric oxide precursor and a compound capable of providing zinc ions. The product can be formulated as a powder and mixed with a liquid in preparation for consumption by a person. The powdered formulation may be mixed with water followed by a... Agent:

20150030699 - Anti-tumor adjuvant therapy: The invention relates to a chimeric peptide construct comprising a cell penetrating peptide linked to a pro-apoptotic peptide, for use in treating a tumor in combination with an anti-tumor agent, preferably a chemotherapeutic agent.... Agent:

20150030700 - Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs: This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide,... Agent:

20150030701 - Antimicrobial compositions and methods: Disclosed are compositions and methods for antimicrobial use. The compositions contain a small antimicrobial agent and a permeabilizing agent. The antimicrobial compositions can be antifungal or antibacterial compositions.... Agent: Yale University

20150030702 - Nitric oxide-generating skin dressings: A skin dressing is provided comprising a first component including a source of protons, a second component including a nitrite salt, the skin dressing further comprising a non-thiol reductant. The skin dressing is adapted, such that, when the first and second components are brought together and applied to a skin... Agent:

20150030703 - Compositions and methods for preferential distribution of active agents to injury sites: Compositions are provided for preferential distribution of active agents to injury sites. Such compositions may comprise a ligand with hydrophilic properties and one or more active agents, such as compounds comprising hydrophilic metal ions. Because the delivery ligand and the active agent are specifically selected so the interactions between them... Agent:

20150030704 - Pyridazinone compounds and their use as daao inhibitors: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Takeda Pharmaceutical Company Limited

20150030705 - Technique and method for producing functional material originated from ice plant, and functional component: The present invention provides a method for producing an ice plant having increased contents of pinitol, β-carotene, vitamin K and proline, said method being characterized by adding a stress to an ice plant during the cultivation of the ice plant; a method for increasing the contents of pinitol, β-carotene, vitamin... Agent:

20150030706 - Use of essential oils, supercritical extracts and aqueous residues generated during a process for obtaining organic extracts from the artemisia absinthium l. plant: The present invention starts with a method for obtaining organic extracts of the Artemisia absinthium L. plant, which includes: a methodology phase for producing said plant, an extraction phase during which said essential oil and a non-volatile extract are obtained, and a phase of extracting supercritical extracts with CO2, and... Agent: Universidad De La Laguna

20150030708 - Compositions comprising extracts of boswellia, tea tree, aloe and lavender oil and methods of treating wounds, burns and skin injuries therewith: Compositions for the treatment of sores, wounds, burns and other traumatized dermal tissues and skin injuries comprising Boswellia gum, gel, resin or extract, Tea Tree oil (Melaleuca oil), an Aloe gel, resin, latex or extract and Lavender oil. The composition may be incorporated into a medical device such as a... Agent:

20150030707 - Rhus coriaria l. extract for use in the treatment of hyperhidrosis: The present invention relates to extracts of Rhus coriaria L. for use in the treatment of hyperhidrosis in humans.... Agent:

20150030709 - Cardio-protective agents from kiwifruits: The invention relates to cardio-protective agents. In particular, the present invention relates to de-sugared cardio-protective extracts and fractions thereof prepared from kiwi fruit.... Agent: University Of Oslo

20150030710 - Compositions comprising extracts or materials derived from palm oil vegetation liquor for inhibition of vision loss due to angiogenesis and method of preparation there: The present invention relates generally to a composition comprising palm fruit juice for use in a method of preventing and inhibiting vision loss due to angiogenesis related diseases. The composition of the present invention aids to decrease in CNV size using confocal microscopy, in addition to reduction in macrophage infiltration... Agent: Malaysian Palm Oil Board

  
  
Previous industry: Chemistry of inorganic compounds
Next industry: Plastic article or earthenware shaping or treating: apparatus


######

RSS FEED for 20150205: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 1.62146 seconds

PATENT INFO